

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Interactions among bone, liver, and adipose tissue predisposing to diabetes and fatty liver.**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/138294> since

*Published version:*

DOI:10.1016/j.molmed.2013.05.006

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



## UNIVERSITÀ DEGLI STUDI DI TORINO

This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process - such as editing, corrections, structural formatting, and other quality control mechanisms - may not be reflected in this version of the text. The definitive version of the text was subsequently published in [*Trends Mol Med. 2013 Sep;19(9):522-35. doi: 10.1016/j.molmed.2013.05.006. Epub 2013 Jun 28*].

You may download, copy and otherwise use the AAM for non-commercial purposes provided that your license is limited by the following restrictions:

- (1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-ND license.
- (2) The integrity of the work and identification of the author, copyright owner, and publisher must be preserved in any copy.
- (3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en>), [*doi: 10.1016/j.molmed.2013.05.006*]

# **Interactions among bone, liver and adipose tissue predisposing to diabetes and fatty liver**

Giovanni Musso M.D.<sup>1\*</sup>, Elena Paschetta M.D.<sup>2\*</sup>, Roberto Gambino PhD<sup>2</sup>, Maurizio Cassader PhD<sup>2</sup>, Federica Molinaro M.D.<sup>2</sup>

\* equal first author

<sup>1</sup> Gradenigo Hospital, University of Turin, Turin, Italy

<sup>2</sup> Dept. of Medical Sciences, San Giovanni Battista Hospital, University of Turin, Turin, Italy

*Corresponding author:*

**Giovanni Musso**

Gradenigo Hospital, Turin

C. <sup>so</sup> R Margherita 8

10132 Turin, Italy

E-mail: [giovanni\\_musso@yahoo.it](mailto:giovanni_musso@yahoo.it)

## **Abstract**

Growing epidemiological evidence connects obesity and its complications, including metabolic syndrome, diabetes and non-alcoholic fatty liver disease (NAFLD) to reduced bone health and osteoporosis. Parallel to human studies, experimental data disclosed a complex network of interaction between adipose tissue, the liver and the bone, which reciprocally modulate each others function. The main mediators of such cross-talk include hormonal/cytokine signals from the bone (osteopontin, osteocalcin and osteoprotegerin), the liver (fetuin-A) and adipose tissue (leptin, TNF- $\alpha$ , adiponectin). Dysregulation of this network promotes the development of diabetes, NAFLD and osteoporosis. We will review recent advances in understanding the mechanisms of bone-liver-adipose tissue interaction predisposing to obesity, diabetes, NAFLD and osteoporosis and their potential clinical implications

## Introduction

Growing epidemiological data link obesity, metabolic syndrome and NAFLD, the hepatic manifestation of metabolic syndrome, to a reduced bone mineral density (BMD) and osteoporosis[1, 2, 3, 4, 5, 6, 7], thereby challenging the conventional belief that excessive body weight prevents bone loss through increased mechanical load to the skeleton and enhanced cortical bone formation[8]. Parallel to human data, cellular and animal models highlighted a complex network of interactions between the bone, adipose tissue and the liver, which mutually modulate their function through the secretion of pro/anti-inflammatory cytokines and hormones[9]. We will review recent mechanistic insights into the cross-talk among these organs, with focus on potential clinical and therapeutic implications for NAFLD, insulin resistance and osteoporosis.

## Osteopontin

Osteopontin(OPN) is a matrix glycoprotein secreted by a variety of cell types including immune cells (activated T-helper 1 cells and macrophages), osteoclasts, endothelial cells, epithelial cells (Table 1)[10]. Human OPN gene consists of seven exons encoding the OPN protein, which contains several highly conserved amino acidic structural sequences for binding integrins, calcium and CD44 receptor (Figure 1). Human OPN gene is subjected to alternative splicing, producing three splice variants (OPN-a, the full-length molecule, OPN-b, lacking exon 5, and OPN-c, lacking exon 4), and the protein undergoes extensive post-translational modifications including serine/threonine phosphorylation, glycosylation, tyrosine sulfation, and proteolytic fragmentation, resulting in molecular isoforms ranging from 25 to 75 kDa[11]. These posttranscriptional and posttranslational modifications generate numerous OPN isoforms, which are cell type specific, depend on physiological and patho-physiological factors, and are likely to affect both OPN binding affinity and biological functions, with potentially relevant diagnostic and therapeutic implications (Table 1; Box 1).

In NAFLD patients, hepatic and plasma OPN expression correlate with the severity of histological steatosis, inflammation and fibrosis[12, 13, 14, 15], and in dietary murine models and cell cultures, OPN expression was required for the development of Nonalcoholic Steatohepatitis (NASH) and insulin resistance, which were prevented or improved by functional or genetic OPN deletion[16, 17, 18, 19, 20]. Furthermore, high (>14.7 ng/mL) serum OPN levels were associated with a 2.96-fold increased risk of osteoporosis in menopausal women, while OPN-deficient mice are resistant to ovariectomy-induced osteoporosis [21, 22, 23].

Numerous mechanisms connecting OPN to liver injury and insulin resistance have been recently described, including enhanced recruitment and activation of circulating monocytes to adipose tissue and liver, activation of hepatic gluconeogenesis through modulation of STAT3 and FOXO1 transcription factors[18, 19](Table 1). Beside recruiting proinflammatory cells to adipose tissue, OPN can also directly bind to its receptors  $\alpha v\beta 1$  and  $\alpha v\beta 5$  integrins on adipocytes and induce insulin resistance and secretion of pro-inflammatory adipokines, thereby promoting adipose tissue dysfunction, a key pathogenic feature of NASH and metabolic syndrome[17, 24](Table 1).

Recent data connect OPN to oxidative stress-induced hepatic fibrogenesis: OPN works as both a soluble cytokine and an extracellular matrix(ECM)-bound protein that can remain intracellular or is secreted, allowing autocrine and paracrine signalling on hepatic stellate cells(HSC)[25]. As a matricellular phosphoglycoprotein, OPN functions as an adaptor and modulator of cell-matrix interactions, regulating cell migration, ECM invasion and cell adhesion through its binding to integrins

Enhanced hepatic OPN expression, which is induced by the hedgehog signalling pathway activation and by reactive oxygen species in damaged hepatocytes, promotes fibrogenesis through HSC activation and recruitment of circulating natural killer T(NKT) cells from the blood[15, 20,25], and has been also connected to growth and metastasis of hepatocellular carcinoma (HCC), an emerging complication of NASH[26, 27, 28, 29, 30, 31, 32] (Table 1; Box 1). Therefore, OPN may contribute to the whole spectrum of severity of liver disease in NAFLD.

In the bone, OPN enhances bone resorption by stimulating osteoclast expression of CD44, which is required for cell motility, and by directly mediating osteoclast attachment to bone ECM: osteoclast activation enhances bone resorption, which in turn releases OPN from ECM into surrounding bone and into the circulation, thus perpetuating local and systemic actions of OPN[9]. Furthermore, animal models demonstrated OPN mediates high fat diet-induced differentiation of bone marrow-derived mesenchymal multipotent stromal cells toward an adipogenic phenotype and away from an osteogenic phenotype, thereby reducing bone deposition[16](Table 1).

Collectively, these data suggest that OPN upregulation may play a pivotal role in obesity-associated insulin resistance, NAFLD and osteoporosis. Future research is needed to clarify the biological activity and impact of distinct osteopontin isoforms on tissue inflammation and metabolism, as well as their clinical utility as a biomarker for progressive liver disease or tumor invasiveness in HCC and as a therapeutic target for the treatment of HCC.

## **Osteocalcin**

Osteocalcin is a 49-amino acid bone matrix noncollagen protein secreted by osteoblasts, which is involved in bone deposition and calcium homeostasis (Table 1). Mounting evidence suggests osteocalcin plays also a major role in energy homeostasis and glucose metabolism: in cross-sectional and prospective epidemiological studies circulating osteocalcin levels are inversely associated with the risk of type 2 diabetes[33, 34], metabolic syndrome[35, 36], overall/abdominal adiposity and insulin resistance[ 37, 38], reduced BMD[39], and with the presence and severity of NAFLD[40, 41, 42, 43]. Gain –of-function and loss-of-function mouse models were consistent with the results of epidemiological studies: genetic osteocalcin deletion induced glucose intolerance, increased fat mass, insulin resistance, decreased expression of insulin target genes in liver and muscle and decreased adiponectin gene expression in adipose tissue, while recombinant osteocalcin

administration improved insulin secretion and sensitivity and prevented high-fat-induced obesity, diabetes and NAFLD[44, 45].

Several mechanisms modulate the secretion and biological activity of osteocalcin (Table 1, Figure 2): in osteoblasts, osteocalcin expression is enhanced by insulin and IGF-1 by relieving the suppression of Runx2 by the transcription factor Twist2[46] and inhibited by the two transcription factors FoxO1 and ATF4 and by ER stress response activation[47, 48, 49, 50, 51]. Furthermore, osteocalcin undergoes posttranslational modification whereby three glutamic acid residues undergo a vitamin K-dependent carboxylation to form  $\gamma$ -carboxyglutamic acid residues (Figure 2).

Carboxylated osteocalcin has a higher affinity for hydroxyapatite and this is thought to be involved in bone extracellular matrix mineralization, while the undercarboxylated form appears to be more metabolically active: however, loss- and gain-of-function mutations in osteocalcin gene demonstrated that osteocalcin is not required for bone ECM mineralization[52], and data regarding the metabolic activity of carboxylated vs. undercarboxylated osteocalcin in humans are not conclusive [37, 44, 53].

Osteocalcin exerts its actions through binding its receptor G protein-coupled receptor family C group 6 member A (GPRC6A), an amino acid-sensing GPCR, highly expressed in a wide variety of tissues, and with considerable multiligand specificity, including L-amino acids, cations, and anabolic steroids in addition to osteocalcin[54](Table 1).

Upon binding to pancreatic  $\beta$ -cell and enteroendocrine L-cells GPRC6A receptors, osteocalcin increases intracellular cAMP and stimulates  $\beta$ -cell proliferation and insulin secretion both directly and through enhanced glucagon-like peptide-1(GLP1) secretion, restoring a normal  $\beta$ -cell function[55, 56]. Notably, the association with enhanced pancreatic insulin secretion has been demonstrated in experimental and epidemiological studies and is the most consistent metabolic effect of osteocalcin to date.

Beside enhancing pancreatic insulin secretion, experimental models suggest osteocalcin may protect against high fat-induced obesity, insulin resistance and NAFLD[50, 51], although epidemiological



human data are conflicting and require further confirmation[57,58]. Several potential mechanisms underlying the insulin-sensitizing, anti-obesogenic and anti-steatotic properties of osteocalcin have been identified in adipocytes, hepatocytes and skeletal myocytes: enhanced adiponectin gene expression in adipocytes[44], reduced endoplasmic reticulum (ER) stress response and NF- $\kappa$ B-mediated inflammation[51], and increased mitochondria biogenesis and function[45] (Table 1). In conclusion, osteocalcin is emerging as an important modulator of energy homeostasis and glucose metabolism in various tissues, raising the possibility that this bone-derived hormone may become a novel treatment for obesity-related disorders, a hypothesis currently being tested.

## **The RANK/RANKL/Osteoprotegerin system**

The receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), a member of the tumor necrosis factor (TNF) superfamily, is an osteoclast differentiation factor expressed mainly, but not exclusively, by osteoblasts as both a trans-membrane and a secretory protein; RANKL binds to its receptor RANK, expressed by mature osteoclasts and osteoclasts progenitors, leading to osteoclast differentiation and activation and consequent bone resorption[59]. The RANKL–RANK interaction is inhibited by osteoprotegerin (OPG) a glycoprotein belonging to the TNF receptor (TNFR) superfamily which is secreted by osteoblasts and acts as a decoy receptor for RANKL: it binds as a homodimer to the homotrimeric RANKL and prevents its binding to RANK, resulting in inhibited osteoclast activation and bone resorption. Studies in vitro confirmed the requirement for OPG dimerization in this process, as the monomeric form has a reduced RANKL-binding affinity [60](Box 2). The relevance of OPG for bone turnover has been demonstrated in vivo, as OPG-deficient mice have decreased bone mineral density[59].

Both OPG and RANKL are expressed in adipocytes and their expression in osteoblasts and adipose cells is modulated by a complex network of interactions involving sex hormones, redox balance, other adipokines, and nuclear transcription factors PPAR- $\gamma$ , PPAR $\beta/\delta$ , and liver X-receptors (LXRs)[61, 62, 63, 64, 65, 66 ](Table 1). In particular, different nuclear transcription factors play a

major role in the interaction between adipose tissue and bone, often with clinically divergent results: the PPAR- $\gamma$  agonists, thiazolidinediones, significantly improve insulin resistance, glucose homeostasis and NASH[67], and PPAR $\beta/\delta$  and LXR agonists are giving encouraging results for the treatment of obesity-related disorders in preclinical and clinical trials[68]. Nevertheless, thiazolidinediones have been associated with bone loss and an increased risk of fractures: while a well-documented mechanism is the reallocation of the fate of bone marrow mesenchymal stem cells to adipocytes rather than to osteoblasts, eventually promoting bone marrow adiposity and bone loss<sup>[69]</sup>, recent evidence suggests that thiazolidinediones increase RANKL and decrease osteoprotegerin expression in osteoblasts, which may also be important for the bone-losing effect of these drugs. Preliminary experimental data suggest if PPAR $\beta/\delta$  and LXR agonists retain the metabolic benefits of thiazolidinediones with no detrimental or even beneficial effects on bone metabolism[65, 66].

Despite promising experimental data, cross-sectional epidemiological studies examining the association between the RANKL/OPG axis and insulin resistance, obesity, bone mineral density and risk of fractures yielded mixed results, finding direct, inverse, or no correlation between with disease states[70, 71, 72, 73, 74], due to several potential reasons: most studies assessed serum RANKL/OPG levels, which may not accurately reflect their tissue levels; commercial ELISA detect all forms of circulating OPG, while only the homodimeric OPG binds RANKL; laboratory measurements of serum RANKL is hampered by the relative instability of this molecule; finally, several factors including age and sex hormonal status may affect RANKL/OPG tissue expression, for example, the interaction between 17 $\beta$ -estradiol and adiponectin in modulating osteoblast RANKL/OPG expression[60, 61].

Recently, reduced serum OPG has been associated with the presence of progressive NASH in NAFLD patients [75]. The anti-inflammatory and antiapoptotic action of OPG may potentially underlie the hepato-protective effects of OPG, furthermore, OPG acts as a decoy receptor for the TNF-related apoptosis-inducing ligand (TRAIL), neutralizing TRAIL-induced apoptosis[59]. As

hepatocyte apoptosis is a key determinant of progression from simple steatosis to NASH, it can be speculated that a defect in OPG production may contribute to liver disease progression in NAFLD [68]. However, two drawbacks may limit the therapeutic use of RANKL antagonists/OPG agonists, i.e. the potential increased risk of malignancy, due to inhibition of TRAIL, which is a potent apoptotic pathway in various tumour cells, and of infections, due to the inhibition of RANK, which is required for activation of various immune system cells, including T cells, monocytes, and dendritic cells. Accordingly, in a randomized controlled trial with denosumab, a human monoclonal antibody against RANKL, a 2% incidence of neoplasm and a 1% incidence of infection occurred in the denosumab groups, whereas neither problem developed in controls[76]. To overcome these limitations, tissue-specific RANKL/OPG modulation is under development, and experimental liver-specific RANKL signalling blockade prevented high fat diet-induced hepatic steatosis, insulin resistance and diabetes in mice[77], with no apparent side effects. Future research will evaluate the feasibility, long-term efficacy and safety of such approach in humans.

## **Fetuin-A**

Fetuin-A ( $\alpha$ 2-Heremans-Schmid glycoprotein,  $\alpha$ 2-HS-glycoprotein), first isolated from fetal bovine serum, is synthesized in the liver and has been implicated in several physiological and pathological conditions, including vascular calcification, regulation of bone metabolism and insulin action, protease activity control, keratinocytes migration, breast tumor cell proliferative signaling and neurodegenerative disease[78]. The relevance of fetuin-A for metabolic disease emerged in gain-of-function and loss-of-function studies: fetuin-A knockout mice exhibit increased glucose tolerance and insulin sensitivity and are resistant to diet-induced obesity, NAFLD and age-associated insulin resistance, conditions that are all induced by fetuin-A administration[79, 80]. In humans, fetuin-A gene is localized on chromosome 3q27, which has been identified as a susceptibility locus for type 2 diabetes and metabolic syndrome[81], and higher serum fetuin-A levels are independently associated with metabolic syndrome components and diabetes, while they are

reduced by pioglitazone treatment[82, 83, 84, 85]. Higher serum and hepatic fetuin-A levels were also associated with the presence of NAFLD and with the severity of liver histology in biopsy-proven NAFLD patients, independently of age, sex, BMI, fasting plasma glucose and triglycerides[86,87, 88] with hepatocyte fetuin-A expression correlating with key enzymes in glucose (phosphoenol pyruvate kinase 1, glucose-6-phosphatase) and lipid (sterol regulatory element-binding protein 1c, carnitine palmitoyltransferase 1) metabolism[89]. Mechanisms underlying fetuin-A regulation and action are being unravelled [90]: fetuin-A inhibits insulin receptor tyrosine kinase activity by inhibiting the autophosphorylation of tyrosine kinase and IRS-1 in skeletal muscle and hepatocytes[78], thereby promoting insulin resistance; fetuin-A directly suppresses adiponectin secretion by adipocytes[80]; furthermore, fetuin-A is a major carrier of free fatty acids (FFA) in the circulation and is required for FFA interaction with toll-like protein receptor 4 (TLR4) in adipocytes, thereby triggering proinflammatory adipokine expression and insulin resistance[91].

Beside its metabolic effects, fetuin-A is also a mineral chaperone in plasma and tissues, facilitating transport and clearing of potentially proinflammatory and procalcific cargo[92, 93]. In

physiological and pathological conditions, tissue mineralization occurs through the interplay of three key determinants: extracellular matrix suitable for mineralization, extracellular levels of inorganic phosphate and calcium, and systemic or local expression of mineralization inhibitors.

Fetuin-A is a prototypic systemic inhibitor protein of mineralization, as it complexes with calcium and phosphate to form stable colloidal mineral-protein spheres called calciprotein particles (CPPs), which are cleared by tissue macrophages and hepatic Kupffer cells through the Scavenger Receptor A[94]. In the bone, fetuin-A regulates matrix mineralization by inhibiting crystallization in the area surrounding the collagen fibril, thereby enabling increased mineralization within the fibril[95].

In vitro, fetuin-A can inhibit or stimulate osteogenesis, depending on its concentrations[96, 97 ]The importance of fetuin-A for bone and systemic matrix mineralization homeostasis *in vivo* emerged in fetuin-A knock-out mice, which show extensive ectopic soft tissue calcification, increased cortical

bone thickness but impaired growth of their long bones and premature growth plate closure due to insufficient inhibition of excessive mineralization in the growth plate cartilage matrix[98].

In epidemiological studies, serum fetuin-A levels were positively associated with BMD in older women, but not in men, in the Health ABC study[99], while in another study they correlated positively with bone turnover biomarkers in diabetic patients[100].

Further research is needed to determine the exact role of fetuin-A in the pathogenesis of metabolic disease, and to elucidate factors interacting with fetuin-A to explain its metabolic and bone-related effects.

## **Leptin**

Encoded by the “ob” gene, leptin is synthesized by mature adipocytes in response to changes in body fat mass and nutritional status. In obesity, plasma leptin levels are increased proportionally to BMI and acutely decrease in response to fasting or restriction of energy intake to a much larger extent than would be expected for smaller reductions of adiposity, thus signaling a negative energy balance[101]. Adipocyte size and anatomical location (subcutaneous) appear to be the major determinants of leptin mRNA expression and secretion, but other factors modulate leptin secretion[101](Table 1). Beside its anorexigenic action in hypothalamus, leptin is an insulin-sensitizing hormone and reduces muscle and hepatic lipid content by promoting FFA  $\beta$ -oxidation, glycolysis and triglyceride assembly into VLDL particles and by inhibiting gluconeogenesis and *de novo* lipogenesis [101, 102, 103](Table 1). Animals devoid of leptin expression, ob/ob mice (leptin gene mutation), db/db mice and fa/fa rats (leptin receptor gene mutations) are obese, insulin resistant and have NAFLD, alterations reversed by leptin administration[104, 105]. Parallel to mice models, in lipotrophic human diabetes, characterized by scarce adipose mass, diminished leptin levels, and markedly elevated intrahepatic triglycerides, leptin administration reduces liver enzymes, BMI, hepatic fat content and histological steatohepatitis[106]. However, in obese patients

leptin levels are normal or elevated, rather than reduced, and correlate with liver fat, thus suggesting the presence of resistance to the beneficial anorexigenic, anti-steatotic and insulin-sensitizing actions of leptin[107]. Mechanisms for hypothalamic leptin resistance have been unraveled, including impaired leptin transport across blood brain barrier[108] and defective intracellular signal transduction through the Jak/STAT pathway, caused by increased expression of the cytokine suppressors of cytokine signaling(SOCS)-3 and of protein tyrosine phosphatase(PTP) 1B, and by activation of I $\kappa$ B kinase  $\beta$  (IKK), JNK and protein kinase C(PKC) $\tau$ [109]. The “compensatory” increase in leptin expression in obesity may enhance the unwanted effects of inappropriate leptin elevation on cells that maintained a normal leptin responsiveness, promoting hepatic inflammation through enhanced Kupffer cells response to circulating bacterial endotoxin[110] and hepatic fibrogenesis through HSC activation[111, 112], thereby promoting steatosis progression to NASH, in rodent models.

Leptin is also an important regulator of bone mass through direct and indirect mechanisms: leptin increases central sympathetic activity by binding to its receptors on both hypothalamic ventromedial (VHM) nucleus and on serotonergic brainstem neurons, which in turn project to VHM neurons[113]. From this nucleus, sympathetic fibers transmit stimuli to effector osteoblasts through the  $\beta$ 2-adrenergic receptor ( $\beta$ 2-AR), inhibiting osteoblast differentiation and undercarboxylate-osteocalcin production [9] (Figure 2, Table 1).

Consistent with the importance of central sympathetic-mediated regulation of bone formation by leptin, obese leptin-deficient *ob/ob* mice showed an increased bone mass which can be rescued by intracerebroventricular (ICV) infusion of leptin and by isoproterenol administration, and leptin receptor-deficient *db/db* mice have a high bone mass, despite elevated circulating leptin<sup>[114, 115]</sup>. Furthermore, chemical lesion of VHM adrenergic signaling results in high bone mass that is resistant to correction by ICV leptin, and  $\beta$ 2-AR disrupted-mice share with *ob/ob* and chemical-injured VHM mice the same bone alteration[116]. Collectively, these experiments, suggest that the predominant effect of leptin on bone is through the central nervous, and are mirrored by the 24–

32% reduction in the risk of fractures experienced by people receiving  $\beta$ -blockers, from several large studies[9].

Notably, none of the aforementioned adrenergic manipulations affect fat or muscle mass[116], suggesting that the leptin/adrenergic pathway for bone mass regulation is dissociated from the leptin pathway controlling adiposity.

Beside sympathetic system modulation, leptin can influence bone metabolism through other pathways(Table 1): leptin receptors have been cloned from osteoblasts and it has been proposed that leptin directly stimulates osteoblast differentiation and bone mineralization[116]; leptin enhances hepatic secretion of insulin-like growth factor binding protein (IGFBP-2), which improves insulin sensitivity and enhances osteoclast differentiation[117, 118]; leptin decreases renal expression of the 25-hydroxyvitamin D3 1 $\alpha$ -hydroxylase gene and increases osteoblast secretion of the phosphaturic factor fibroblast growth factor 23 (FGF-23), with consequent reduction in phosphate resorption and in the synthesis of 1 $\alpha$ ,25-dihydroxyvitamin D3 [1,25(OH)<sub>2</sub>D<sub>3</sub>] [119].

The relative importance of these often divergent pathways *in vivo*, the effect of leptin interaction with age, sexual hormones and other bone-regulating cytokines, remain to be established and may explain the somewhat controversial epidemiological association of leptin with bone turnover and mineral density[120, 121].

## **Tumor necrosis factor (TNF)- $\alpha$**

The proinflammatory cytokine tumor necrosis factor (TNF- $\alpha$ ) is produced by adipocytes, activated macrophages and Kupffer cells and promotes hepatic and systemic inflammation, liver injury and insulin resistance by interacting with TNF-R1 and TNF-R2: TNF-R1 mediates apoptosis and lipolysis while TNF-R2 induces insulin resistance[122].

In adipocytes, TNF- $\alpha$  reduces secretion of leptin and adiponectin and induces insulin resistance by reducing GLUT-4 expression and lipoprotein lipase (LPL) activity and by increasing expression of hormone sensitive lipase[123]. TNF- $\alpha$  also impairs insulin signaling in adipocytes and hepatocytes

through activation of stress-related protein kinases, such as JNK-1, and of the inhibitor kappa kinase beta (IKK $\beta$ )/nuclear factor kappa B (NF- $\kappa$ B) pathway, resulting in a state of chronic low-grade inflammation and increased production of cytokines, including TNF- $\alpha$  and interleukin (IL)-6, that perpetuate hepatic and systemic insulin resistance[122].

Substantial experimental evidence points to TNF- $\alpha$  as a key mediator of liver injury and steatohepatitis: in the methionine-choline deficient (MCD) animal model of NASH, anti-TNF- $\alpha$  antibody administration ameliorated necrosis, inflammation and fibrosis[124]. Furthermore, inhibition of hepatic TNF- $\alpha$  production and TNF- $\alpha$  knockout improved high fat diet-induced steatohepatitis and hepatic insulin resistance[122]. Adipocyte and hepatic TNF- $\alpha$  expression have been strongly associated with the severity of NASH and of insulin resistance in humans, though the correlation between circulating levels of this cytokine and the severity of liver injury was somewhat variable across studies [122, 125].

In the bone, TNF- $\alpha$  promotes osteoclastogenesis while simultaneously inhibiting the activation of osteoblasts from their progenitor cells. TNF- $\alpha$  increases the expression of M-CSF and RANKL which promotes osteoclast differentiation, in several target cells including osteoblasts; TNF- $\alpha$  promotes osteoclast differentiation both directly through binding to TNF-R1 and activating NF- $\kappa$ B pathway activation and indirectly by mediating RANKL stimulation of osteoclast differentiation by an autocrine mechanism[126]; furthermore, TNF- $\alpha$  has also been shown to inhibit osteoclast apoptosis through mammalian target of rapamycin/S6 kinase activation[127].

Through binding to osteoblast TNF-R1, TNF- $\alpha$  inhibits their proliferation and differentiation and increases apoptosis of their progenitors; these effects appear to be mediated primarily via activation of multiple downstream signaling pathways[128,129], including a reduced RUNX2 expression through its ubiquitynation and an inactivation of pro-osteogenic mitogen-activated protein kinase (MAPK)[127]. Furthermore, TNF- $\alpha$  inhibits the expression of genes involved in bone formation, including alkaline phosphatase, vitamin D receptor, parathyroid hormone receptor[130].



## Adiponectin

The adipokine adiponectin has been most robustly and inversely associated with the incidence and severity of different metabolic disorders, including diabetes, obesity, metabolic syndrome and NAFLD in experimental and epidemiological studies [131, 132]. Consistently, recombinant adiponectin administration markedly improved metabolic profile and liver histology in animal models of NASH[133], through its potent insulin-sensitizing, anti-lipogenic, anti-oxidative/inflammatory, anti-inflammatory and anti-fibrotic properties (Table 1). Experimental studies showed adiponectin can modulate bone turnover through binding its specific receptors on osteoblasts and osteoclasts: adiponectin promotes osteoblasts proliferation, differentiation and activity and enhances RANKL secretion while inhibiting osteoprotegerin secretion; in osteoclasts, adiponectin inhibits RANKL-mediated osteoclastogenesis through interaction with its adaptor molecule APPL1 *in vitro*[61, 62, 134, 135]. Despite this consistent experimental evidence, epidemiological studies reported conflicting results: most studies reported an inverse relationship between serum adiponectin, BMD or fracture risk and a positive relationship with bone turnover markers[136,137, 138], other studies showed a positive correlation[139], while other studies found no association[140]. Several reasons may underlie the epidemiological discrepancy: all studies evaluated circulating, and not bone adiponectin levels, which may differ considerably; furthermore, adiponectin should not be considered in isolation, but rather adiponectin-related signaling in bone should be considered within the network of hormonal and cytokine signals that influence both adiponectin secretion/action and skeleton biology, including sexual hormones, undercarboxylated osteocalcin and osteoprotegerin/RANKL axis[62, 141].

## Concluding remarks

Emerging experimental and epidemiological evidence disclosed a complex cytokine and hormonal cross-talk among bone cells the liver and adipose tissue, which coordinately regulates bone

remodeling, energy metabolism and glucose homeostasis; alterations in this network may contribute to the pathogenesis of obesity and related disorders, including NAFLD and diabetes. Future research will have to elucidate the clinical relevance of such alterations for human disease, and the potential use for screening purposes, i.e. to identify subjects at increased risk of developing such complications, and for therapeutic purposes.

**Conflict of interest statement:** the author has no present or past conflict of interest to disclose

## **BOXES**

### **Box 1: Osteopontin and hepatocellular carcinoma (HCC)**

HCC cells overexpress OPN, and its expression correlates with tumor invasiveness and metastasis: consequently, plasma OPN levels or OPN gene polymorphisms have been proposed as potential diagnostic and prognostic biomarkers for HCC[28, 29]. OPN isoforms seem to play different activities in HCC growth and metastasis: Chae et al. found that hepatocellular carcinoma cells (HCCs) predominantly expressed OPNa and OPNb splice variants, while normal hepatocytes expressed OPNc *in vivo*; in cell proliferation and invasion assays, OPNa and OPNb induced Hep3B cell migration, while OPNc had no significant effects. By contrast, OPNc suppressed the migratory activity of SK-Hep1 cells[31]. OPN antagonism by blocking antibodies to inhibit iOPN binding to receptors or by directly decreasing tumor OPN expression through small interfering RNA (siRNA) suppressed HCC cells migration, invasion and neoangiogenesis *in vitro*, decreased metastases and improved survival *in vivo*[27, 30].

### **BOX 2: Intracellular signaling mechanism of RANKL-RANK-OPG system**

The RANKL–RANK interaction leads to the recruitment of TNF receptor-associated factors (TRAFs) to the intracellular domain of RANK, among which TRAF6 seems to have a central role

for the osteoclasts resorptive activity. TRAFs recruitment activates many downstream targets, which lead to osteoclast differentiation (transcription factor NF- $\kappa$ B, p38, JNK mitogen-activated protein kinases -MAPKs) and survival (PI3K/Akt/mTOR signalling pathway, MAPK extracellular signal-related kinase - ERK). RANKL seems to support osteoclast formation as a membrane-associated factor, while its role as a soluble form is still debatable: activated T cell, which have been found involved in the osteoclastogenesis in rheumatoid arthritis, produce membrane-anchored RANKL that is shed by metalloprotease-disintegrin TNF $\alpha$  convertase (TACE) to form soluble RANKL (sRANKL). OPG produced by osteoblasts exerts osteoprotective effects by inhibiting the RANKL-RANK interaction, binding as a homodimer to the homotrimeric RANKL, thus preventing its binding to RANK and subsequent osteoclast activation.

### **BOX Outstanding Questions**

- what is the biological and clinical impact of distinct osteopontin isoforms on tissue inflammation, cancerogenesis and metabolism?
- can these novel hormones/cytokines (osteocalcin, osteopontin, osteoprotegerin/RANKL, fetuin-A) be used as biomarkers to screen subjects at increased risk for more severe liver-related, metabolic and osteoporotic disease?
- are these novel hormones/cytokines accurate just biomarkers or do they play a causal role for the pathogenesis of human diseases?
- what are the exact biological mechanisms and clinical impact of adiponectin on the pathogenesis of osteoporosis?
- what is the role of oxidative stress in the modulation of the bone-liver-adipose tissue axis and in the pathogenesis of obesity-associated osteoporosis?

### **GLOSSARY**

**Alternative splicing:** the process whereby identical pre-mRNA molecules are spliced in different ways, eventually leading to splice variants coding distinct proteins with different biological functions. Alternative splicing is important for both normal development and disease processes

**Adaptor protein containing pleckstrin homology domain, phosphotyrosine domain, and leucine zipper motif (APPL1):** the first identified protein interacting with adiponectin receptors. It is suggested to be an adaptor protein responsible for intracellular mediation of adiponectin signal transduction

**Activating transcription factor 4 (ATF4):** a member of the cAMP-responsive element-binding protein transcription factor family, that is regulated by sympathetic tone, and regulates osteoblast endocrine functions by inducing Esp and Ocn

**Extracellular signal-regulated protein kinase (ERK):** ERK1 and ERK2 are related protein-serine/threonine kinases that participate in the Ras-Raf-MEK-ERK signal transduction cascade, involved in the regulation of a large variety of processes including cell adhesion, cell cycle progression, cell migration, cell survival, differentiation, metabolism, proliferation, and transcription

**Forkhead box protein O1 (FOXO1):** one of the four FoxO isoforms of Forkhead transcription factors, highly expressed in insulin-responsive tissues, including pancreas, liver, skeletal muscle, adipose tissue, bone. FoxO1 orchestrates the transcriptional cascades regulating glucose metabolism, insulin sensitivity and energy expenditure.

**Jak/STAT:** The janus kinase (Jak)–signal transducer and activator of transcription (STAT) pathway is a major intracellular signalling pathway activated by leptin.

**c-Jun NH2-terminal kinase (JNK):** a MAPK family member that mediates cellular responses to several stressing stimuli, including TNF, free fatty acids (FFAs) and reactive oxygen species (ROS). Activated JNK1 and JNK2 isoforms phosphorylate the AP-1 subunit c-Jun, increasing its transcriptional activity.

**Mitogen-activated protein kinase (MAPK):** The MAPK family includes a set of protein kinases that sequentially activate each other to regulate many processes including cell growth,

differentiation, cell survival, and the immune function in response to a wide range of extracellular stimuli including growth factors, hormones, and cytokines.

**Osteoprotegerin (OPG):** also known as tumor necrosis factor receptor superfamily member 11B, is a cytokine receptor and a member of the TNF receptor superfamily. Osteoprotegerin is a decoy receptor for RANKL. By binding to RANKL, OPG inhibits NF- $\kappa$ B-mediated activation of osteoclasts.

**Receptor activator of nuclear factor  $\kappa$ -B ligand (RANKL):** a member of the tumor necrosis factor (TNF) cytokine family. RANKL is a ligand for osteoprotegerin and a key factor for osteoclast differentiation and activation, and in T helper cells is involved in dendritic cell maturation.

**Runt-related transcription factor 2 (Runx2):** a runt domain-containing transcription factor that is a transcriptional activator of osteoblast differentiation and master gene for bone development.

**Signal transducer and activator of transcription 3 (STAT3):** a members of the STAT transcription factor family, implicated in signal transduction by different cytokines, growth factors and oncogenes

**TNF-related apoptosis-inducing ligand (TRAIL):** A cytokine produced by immune cells, such as monocytes, in response to interferon  $\alpha$  and  $\gamma$ . It activates tumor cell apoptotic signaling pathways through the death receptors DR4 and DR5: OPG binds to TRAIL thus preventing its interaction with the functional death receptors and allowing cells to escape apoptosis.

## FIGURE LEGENDS

### **Figure 1: Osteopontin molecular structure and interactions**

Osteopontin binds to integrins, transmembrane and dimeric proteins consisting of  $\alpha$  and  $\beta$  subunits. It has several cell interacting domains that facilitate integrin binding in different cell types: an arginine-glycine-aspartic acid (RGD) cell binding sequence, which interacts with cell surface integrins  $\alpha v\beta 3$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 5$  and  $\alpha 8\beta 1$ ; a serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR)-containing domain, located between the RGD sequence and the thrombin cleavage site, which interacts with  $\alpha 9\beta 1$ ,  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$ ; A ELVTDFDLPAT domain is also reported to bind to  $\alpha 4\beta 1$ ; A calcium binding site and 2 heparin binding domains also exist: the heparin binding domains bind CD44 receptor. Furthermore, OPN can be cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). *In vitro*, fragments generated by cleavage expose new active domains that may impart new activities.

### **Figure 2: regulation of osteoblast endocrine activity and osteocalcin secretion**

In osteoblasts, undercarboxylated osteocalcin (uc-OCN) undergoes posttranslational modification whereby three glutamic acid residues are carboxylated to form  $\gamma$ -carboxyglutamic acid residues (carboxylated osteocalcin, carboxy-OCN). In animal studies, the undercarboxylated form appeared to mediate the metabolic effects of osteocalcin (i.e. increased  $\beta$ -cell proliferation, insulin secretion, insulin sensitivity and adiponectin and adiponectin expression, while carboxy-OCN has a lower metabolic bioactivity and higher affinity for hydroxyapatite and this is thought to be involved in bone extracellular matrix mineralization[52], although conclusive data in humans are lacking. The *Esp* gene, expressed only in osteoblasts, embryonic stem cells, and Sertoli cells, codes for the protein tyrosine phosphatase osteotesticular protein tyrosine phosphatase (OST-PTP), which induces osteocalcin  $\gamma$ -carboxylation in a vitamin K-dependent reaction, thereby reducing osteocalcin metabolic bioactivity.

The endocrine function of osteoblasts is regulated by 2 transcription factors, the Activating Transcription Factor 4 (ATF4) and the Forkhead transcription factor FoxO1. ATF4 belongs to the cAMP-responsive element-binding protein transcription factor family, is upregulated by sympathetic nervous system (SNS) activation and induces *Esp* and *Ocn* gene expression, with the ultimate effect of promoting glucose intolerance and insulin resistance: consistently, osteoblast-specific ATF4 deletion enhanced glucose tolerance and insulin sensitivity[50]. The transcription factor FoxO1 synergizes with ATF4 by reducing *Ocn* gene transcription and inducing *Esp* gene transcription, with the final result of reducing osteocalcin expression and promoting its carboxylation. Accordingly, osteoblast-specific FoxO1 deletion reduced osteoblast OST-PTP expression, increased osteocalcin and protected against obesity, diabetes and NAFLD[47].

FoxO1 inhibits *Ocn* gene expression by interacting with the *Ocn* gene-promoting transcription factor Runx2 and suppressing its binding to its cognate site within the *Ocn* promoter region[48]. Insulin and IGF-1 stimulate osteoblast differentiation and osteocalcin expression by relieving the suppression of Runx2 by Twist2 [46]. Insulin and IGF-1 antagonize FoxO1 activity by promoting its phosphorylation through the PI3K/AKT-dependent pathway: FoxO1 phosphorylation (P-FoxO1) results in its nuclear exclusion and inhibition of target gene expression[48]. FoxO1 inactivation favours osteocalcin activity in a dual mode of action. On one hand, it down-regulates expression of *Esp* thereby promoting osteocalcin decarboxylation. On the other hand, it reduces production of the anti-osteoclastogenic factor osteoprotegerin (*Opg*), and promotes osteoclastogenesis and bone resorption[48]. Through these feedback pathways, one at the transcriptional level with FoxO1 and the other at the hormonal level with osteocalcin, the skeleton and pancreas interact to tightly regulate energy metabolism and bone turnover.

Homocysteine is another factor regulating osteoblast endocrine activity: it inhibits osteoprotegerin by inducing FOXO1 loss through protein phosphatase 2A (PP2A) phosphorylation and enhances RANKL expression by activating JNK MAP kinase signalling pathway[63].

Another important regulator of osteoblast differentiation and osteocalcin secretion is sympathetic nervous system (SNS), which inhibits osteoblast differentiation and ucOC formation. The clinical importance of  $\beta$ 2-mediated sympathetic tone, which is the main effector of the indirect effects of leptin on osteoblast activity, for bone health is suggested by the 24–32% reductions in the risk of fractures experienced by people receiving  $\beta$ -blockers emerged in several large studies[9].



## BOXES

### **Box 1. Osteopontin and hepatocellular carcinoma(HCC).**

HCC cells overexpress OPN, and its expression correlates with tumor invasiveness and metastatization: consequently, plasma OPN levels or OPN gene polymorphisms have been proposed as potential diagnostic and prognostic biomarkers for HCC[28, 29].

OPN isoforms seem to play different activities in HCC growth and metastatization: Chae et al.

found that hepatocellular carcinoma cells (HCCs) predominantly expressed

OPNa and OPNb splice variants, while normal hepatocytes expressed OPNc *in vivo*; in cell

proliferation and invasion assays, OPNa and OPNb induced Hep3B cell migration, while OPNc had no significant effects. By contrast, OPNc suppressed the migratory activity of SK-Hep1 cells[31].

OPN antagonization by blocking antibodies to inhibit iOPN binding to receptors or by directly decreasing tumor OPN expression through small interfering RNA (siRNA) suppressed HCC cells migration, invasion and neoangiogenesis *in vitro*, decreased metastases and improved survival *in vivo*[27, 30].

### **BOX 2. Intracellular signaling mechanism of RANKL-RANK-OPG system**

The RANKL–RANK interaction leads to the recruitment of TNF receptor-associated factors (TRAFs) to the intracellular domain of RANK, among which TRAF6 seems to have a central role for the osteoclasts resorptive activity. TRAFs recruitment activates many downstream targets, which lead to osteoclast differentiation (transcription factor NF- $\kappa$ B, p38, JNK mitogen-activated protein kinases -MAPKs) and survival (PI3K/Akt/mTOR signalling pathway, MAPK extracellular signal-related kinase - ERK).

RANKL seems to support osteoclast formation as a membrane-associated factor, while its role as a soluble form is still debatable: activated T cell, which have been found involved in the osteoclastogenesis in rheumatoid arthritis, produce membrane-anchored RANKL that is shedded by metalloprotease-disintegrin TNF $\alpha$  convertase (TACE) to form soluble RANKL (sRANKL).

OPG produced by osteoblasts exerts osteoprotective effects by inhibiting the RANKL-RANK interaction, binding as a homodimer to the homotrimeric RANKL, thus preventing its binding to RANK and subsequent osteoclast activation.

## GLOSSARY

**Alternative splicing:** the process whereby identical pre-mRNA molecules are spliced in different ways, eventually leading to splice variants coding distinct proteins with different biological functions. Alternative splicing is important in both normal development and disease processes

**APPL1** (adaptor protein containing pleckstrin homology domain, phosphotyrosine domain, and leucine zipper motif). the first identified protein interacting with adiponectin receptors and is suggested to be an adaptor protein responsible for intracellular mediation of adiponectin signal transduction

**ATF4:** activating transcription factor 4, belongs to the cAMP-responsive element-binding protein transcription factor family, is regulated by sympathetic tone, and regulates osteoblast endocrine functions by inducing *Esp* and *Ocn*

**ERK:** extracellular signal-regulated protein kinase. ERK1 and ERK2 are related protein-serine/threonine kinases that participate in the Ras-Raf-MEK-ERK signal transduction cascade, involved in the regulation of a large variety of processes including cell adhesion, cell cycle progression, cell migration, cell survival, differentiation, metabolism, proliferation, and transcription

**FOXO1:** Forkhead box 01

**Jak/STAT:** janus kinase (JAK)–signal transducer and activator of transcription (STAT) pathway , a major intracellular signalling pathway for leptin. Leptin binds to its receptor OB-Rb and activates the receptor-associated kinase JAK2 via transphosphorylation and phosphorylates three tyrosine residues(Y985, Y1077, and Y1138 in mice).The signals emanating from the LepRTyr985

control hepatic insulin sensitivity. Leptin stimulates JAK2-dependent phosphorylation and nuclear translocation of the transcription factor signal transducer and activator of STAT3. In the liver, STAT3 regulates glucose homeostasis by suppressing the expression of gluconeogenic genes; in the hypothalamus, pSTAT3 translocates to the nucleus, where it increases the expression of proopiomelanocortin (POMC) and inhibits that of NPY.

**JNK:** c-Jun NH<sub>2</sub>-terminal kinase

**MAPK:** mitogen-activated protein kinase


**Osteoprotegerin (OPG):** also known as tumor necrosis factor receptor superfamily member 11B, is a cytokine receptor and a member of the tumor necrosis factor (TNF) receptor superfamily. Osteoprotegerin is a decoy receptor for RANKL. By binding to RANKL, OPG inhibits NF- $\kappa$ B-mediated activation of osteoclasts.

**RANKL(Receptor activator of nuclear factor  $\kappa$ -B ligand):** a member of the tumor necrosis factor (TNF) cytokine family. RANKL is a ligand for osteoprotegerin and a key factor for osteoclast differentiation and activation, and in T helper cells is involved in dendritic cell maturation.

**Runx2:** a runt domain-containing transcription factor that is a transcriptional activator of osteoblast differentiation and master gene for bone development.

**STAT3:** signal transducer and activator of transcription 3

**TRAIL(TNF-related apoptosis-inducing ligand).** TRAIL is produced by immune cells, such as monocytes, in response to interferon  $\alpha$  and  $\gamma$ . This cytokine activates tumor cell apoptotic signalling pathways through the death receptors DR4 and DR5: OPG binds to TRAIL thus preventing its interaction with the functional death receptors and allowing cells to escape apoptosis.



**Figure 1 Osteopontin molecular structure and interactions.**

Osteopontin binds to integrins, transmembrane and dimeric proteins consisting of  $\alpha$  and  $\beta$  subunits. It has several cell interacting domains that facilitate integrin binding in different cell types:

- an arginine-glycine-aspartic acid (RGD) cell binding sequence, which interacts with cell surface integrins  $\alpha5\beta3$ ,  $\alpha5\beta1$ ,  $\alpha5\beta5$  and  $\alpha8\beta1$ .
- A serine-valine-valinetyrosine-glutamate-leucine-arginine (SVVYGLR)-containing domain, located between the RGD sequence and the thrombin cleavage site, which interacts with  $\alpha9\beta1$ ,  $\alpha4\beta1$  and  $\alpha4\beta7$
- A ELVTDFDLPAT domain is also reported to bind to  $\alpha4\beta1$
- A calcium binding site and 2 heparin binding domains also exist: the heparin binding domains bind CD44 receptor.

Furthermore, OPN can be cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). *In vitro*, fragments generated by cleavage expose new active domains that may impart new activities.

## Figure 2. mechanisms regulating secretion and biological activity of osteocalcin

In osteoblasts, uncarboxylated osteocalcin (uc-OCN) undergoes posttranslational modification whereby three glutamic acid residues are carboxylated to form  $\gamma$ -carboxyglutamic acid residues (carboxylated osteocalcin, carboxy-OCN). In animal studies, the uncarboxylated form appeared to mediate the metabolic effects of osteocalcin (i.e. increased  $\beta$ -cell proliferation, insulin secretion, insulin sensitivity and adiponectin and adiponectin expression, while carboxy-OC has a lower metabolic bioactivity and higher affinity for hydroxyapatite and this is thought to be involved in bone extracellular matrix mineralization, although conclusive data in humans are lacking. The *Esp* gene, expressed only in osteoblasts, embryonic stem cells, and Sertoli cells, codes for the protein tyrosine phosphatase osteotesticular protein tyrosine phosphatase (OST-PTP), which induces osteocalcin  $\gamma$ -carboxylation in a vitamin K-dependent reaction, thereby reducing osteocalcin metabolic bioactivity.

The endocrine function of osteoblasts is regulated by 2 transcription factors, the Activating transcription factor 4 (ATF4) and the Forkhead transcription factor FoxO1. ATF4 belongs to the cAMP-responsive element-binding protein transcription factor family, is upregulated by sympathetic nervous system (SNS) activation and induces *Esp* and *Ocn* gene expression, with the eventual effect of promoting glucose intolerance and insulin resistance: consistently, osteoblast-specific ATF4 deletion enhanced glucose tolerance and insulin sensitivity (Kode JBC 2012, 48). The transcription factor FoxO1 synergizes with ATF4 by reducing *Ocn* gene transcription and inducing *Esp* gene transcription, with the eventual result of reducing osteocalcin expression and promoting its carboxylation. Accordingly, osteoblast-specific FoxO1 deletion reduced osteoblast OST-PTP expression, increased osteocalcin and protected against obesity, diabetes and fatty liver (Rached JCI 2010, 46).

FoxO1 inhibits *Ocn* gene expression by interacting with the *Ocn* gene-promoting transcription factor Runx2 and suppressing its binding to its cognate site within the *Ocn* promoter region (Yang IBC 2011, 47)

Insulin and IGF-1 stimulate osteoblast differentiation and osteocalcin expression by relieving the suppression of Runx2 by Twist2 (46 Fulzele 2010). Insulin and IGF-1 antagonize FoxO1 activity by promoting its phosphorylation through the PI3K/AKT-dependent pathway: FoxO1 phosphorylation (P-FoxO1) results in its nuclear exclusion and inhibition of target gene expression (Yang IBC 2011, 47). FoxO1 inactivation favours Osteocalcin activity in a dual mode of action. On one hand, it down-regulates expression of *Esp* thereby promoting Osteocalcin decarboxylation. On the other hand, it reduces production of the anti-osteoclastogenic factor Osteoprotegerin (*Opg*), and promotes osteoclastogenesis and bone resorption (Ferron M., Cell, 2010;48). Through these feedback pathways, one at the transcriptional level with FoxO1 and the other at the hormonal level with osteocalcin, the skeleton and pancreas interact to tightly regulate energy metabolism and bone turnover.

Homocysteine inhibits osteoprotegerin by inducing FOXO1 loss through protein phosphatase 2A (PP2A) phosphorylation and enhances RANKL expression by activating JNK MAP kinase signalling pathway (62 Vijayan FRBM 2013).


Another important regulator of osteoblast differentiation and osteocalcin secretion is sympathetic nervous system (SNS), which inhibits osteoblast differentiation and ucOC formation. The clinical importance of sympathetic tone, which mediates part of the indirect effects of leptin on osteoblast activity, for bone health is suggested by the 24–32% reduction in the risk of fractures experienced by people receiving  $\beta$ -blockers emerged in several large studies

## **Figure 2. Endocrine connection between osteoblasts and adipocytes**


The transcriptional factor FoxO1 is also expressed in osteoblasts (OB). Osteoblast-specific FoxO1 deficiency is associated with an anabolic metabolism profile due to increased osteocalcin expression and decreased expression of *Esp*. In addition, osteocalcin may stimulate adipose tissue to secrete adiponectin, an insulin-sensitizing factor. Adipocytes (AD) affect bone and energetic metabolism by secreting leptin. In the CNS leptin stimulates the sympathetic nervous system (SNS) thereby activating the  $\beta$ 2-adrenergic receptor (Adr $\beta$ 2) in bone and subsequently

decreasing OB proliferation. Leptin also improves insulin sensitivity and this effect may be, at least in part, mediated by IGFBP2.

Osteocalcin bioactivity can be regulated in a bimodal mechanism of action. In the first mechanism osteocalcin activity is negatively regulated by another gene expressed in osteoblasts, *Esp*. Protein-tyrosine phosphatase (OST-PTP), the product of *Esp*, decreases osteocalcin bioactivity by favoring its carboxylation (2). In the second mechanism bone resorption induces a change in the pH that spontaneously decarboxylates and activates osteocalcin (3). Respective to the latter mechanism, we did not detect any increases in osteoclast function in *FoxO1osb*  $_{-/-};Atf4_{-/-}$  mice that would indicate an increase in bone resorption (Fig. 5G).



**Osteoblast signaling pathways involved in energy metabolism regulation.** Effects of insulin and sympathetic nervous system (SNS) on osteocalcin (OCN), osteostic protein tyrosine phosphatase (OST-PTP), and osteoprotegerin (OPG). Adrβ2, β2-adrenergic receptor; ATF4, activating transcription factor 4; InsR, insulin receptor. Adapted from Confavreux.<sup>22</sup>



**Insulin and bone resorption affect circulating uncarboxylated osteocalcin (Glu-OCN).**

Insulin binds its receptor (InsR), which reduces osteoprotegerin (OPG) expression, thus enhancing osteoclast formation and activity. During bone resorption, acidification of the extracellular compartment decarboxylates inactive osteocalcin (Gla-OCN) to Glu-OCN. Glu-OCN is then released into the blood stream to affect target tissues. OST-PTP, osteotesticular protein tyrosine phosphatase. Adapted from *Cell*,<sup>27</sup> with permission from Elsevier.

**Table 1. Effect of β-blockers on fracture risk<sup>12</sup>**

[Figures and tables index](#)

Study	Study design	Subjects	Fracture type	Hazard or odds ratio (95% CI)	Reference
SOF	Prospective cohort	8412 (13.1% users)	Hip	0.76 (0.58–0.99)	Reid <i>et al.</i> <sup>10</sup>
GPRD	Retrospective case-control	120,819 controls (17.6% users), 30,601 cases (16% users)	Any	0.77 (0.72–0.83)	Schlienger <i>et al.</i> <sup>11</sup>
			Hip	0.68 (0.52–0.89)	
Geelong Osteoporosis Study	Population-based case-control	775 controls (14.5% users), 569 cases (10.4% users)	Any	0.69 (0.49–0.96)	Pasco <i>et al.</i> <sup>9</sup>

Abbreviations: CI, confidence interval; GPRD, General Practice Research Database; SOF, Study of Osteoporotic Fractures.

**BOX 2. The RANKL-RANK-OPG system**

OPG regulates bone turnover through the RANKL-RANK system. The receptor activator of nuclear factor-κB ligand (RANKL), a member of the TNF superfamily, is an osteoclast differentiation factor expressed by osteoblasts as a transmembrane protein; RANKL binds to its receptor RANK, which is expressed by both mature osteoclasts and osteoclasts progenitors, leading to osteoclast differentiation and activation and consequently bone resorption.



The RANKL–RANK interaction leads to the recruitment of TNF receptor-associated factors (TRAFs) to the intracellular domain of RANK, among which TRAF6 seems to have a central role for the osteoclasts resorptive activity. TRAFs recruitment activates many downstream targets, which lead to osteoclast differentiation (transcription factor NF- $\kappa$ B, p38, JNK mitogen-activated protein kinases -MAPKs) and survival (PI3K/Akt/mTOR signalling pathway, MAPK extracellular signal-related kinase - ERK).

RANKL seems to support osteoclast formation as a membrane-associated factor, while its role as a soluble form is still debatable: activated T cell, which have been found involved in the osteoclastogenesis in rheumatoid arthritis, produce membrane-anchored RANKL that is shedded by metalloprotease-disintegrin TNF $\alpha$  convertase (TACE) to form soluble RANKL (sRANKL). OPG produced by osteoblasts exerts osteoprotective effects by inhibiting the RANKL-RANK interaction, binding as a homodimer to the homotrimeric RANKL, thus preventing its binding to RANK and subsequent osteoclast activation.


Besides the regulation of bone turnover, the RANKL-RANK-OPG system affects the immune system. The interaction between T cell-derived RANKL with RANK on the surface of the dendritic cells (DC) enhances activation and survival of DC, T cell and monocytes/macrophages; OPG administration leads to a reduction in DC survival, suggesting that OPG may downregulate the immune response inhibiting the RANKL-RANK binding also on immune cells.

Both OPG and RANKL mRNAs are expressed in adipocytes, under the regulation of TNF-  $\alpha$ , insulin and Rosiglitazone. The elevation of RANKL by TNF $\alpha$  could stimulate angiogenesis in adipose tissue, while insulin and rosiglitazone suppress OPG: both these pathways lead to adipose tissue growth.

OPG exerts anti-apoptotic properties by acting as soluble receptor for TNF related activation induced ligand (TRAIL). TRAIL is produced by immune cells, such as monocytes, within the tumour microenvironment in response to interferon  $\alpha$  and  $\gamma$ . This cytokine activates tumor cell apoptotic signalling pathways through the death receptors DR4 and DR5: OPG binds to TRAIL thus preventing its interaction with the functional death receptors and allowing cells to escape apoptosis.

OPG can also promote endothelial cell survival. As non-malignant cell are unresponsive to TRAIL, the mechanism underlying OPG-mediated increase in endothelial cells survive remain to be identified.

Figure 2. Osteoclast



### **Figure 1 Osteopontin molecular structure and interactions.**

Osteopontin binds to integrins, transmembrane and dimeric proteins consisting of  $\alpha$  and  $\beta$  subunits. It has several cell interacting domains that facilitate integrin binding in different cell types:

- an arginine-glycine-aspartic acid (RGD) cell binding sequence, which interacts with cell surface integrins  $\alpha v\beta 3$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 5$  and  $\alpha 8\beta 1$ .
- A serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR)-containing domain, located between the RGD sequence and the thrombin cleavage site, which interacts with  $\alpha 9\beta 1$ ,  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$
- A ELVTDFDLPAT domain is also reported to bind to  $\alpha 4\beta 1$
- A calcium binding site and 2 heparin binding domains also exist: the heparin binding domains bind CD44 receptor.

Furthermore, OPN can be cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). *In vitro*, fragments generated by cleavage expose new active domains that may impart new activities.

## Figure 2. mechanisms regulating secretion and biological activity of osteocalcin

In osteoblasts, uncarboxylated osteocalcin (uc-OCN) undergoes posttranslational modification whereby three glutamic acid residues are carboxylated to form  $\gamma$ -carboxyglutamic acid residues (carboxylated osteocalcin, carboxy-OCN). In animal studies, the uncarboxylated form appeared to mediate the metabolic effects of osteocalcin (i.e. increased  $\beta$ -cell proliferation, insulin secretion, insulin sensitivity and adiponectin and adiponectin expression, while carboxy-OC has a lower metabolic bioactivity and higher affinity for hydroxyapatite and this is thought to be involved in bone extracellular matrix mineralization, although conclusive data in humans are lacking. The *Esp* gene, expressed only in osteoblasts, embryonic stem cells, and Sertoli cells, codes for the protein tyrosine phosphatase osteotesticular protein tyrosine phosphatase (OST-PTP), which induces osteocalcin  $\gamma$ -carboxylation in a vitamin K-dependent reaction, thereby reducing osteocalcin metabolic bioactivity.

The endocrine function of osteoblasts is regulated by 2 transcription factors, the Activating transcription factor 4 (ATF4) and the Forkhead transcription factor FoxO1. ATF4 belongs to the cAMP-responsive element-binding protein transcription factor family, is upregulated by sympathetic nervous system (SNS) activation and induces *Esp* and *Ocn* gene expression, with the eventual effect of promoting glucose intolerance and insulin resistance: consistently, osteoblast-specific ATF4 deletion enhanced glucose tolerance and insulin sensitivity (Kode JBC 2012, 48). The transcription factor FoxO1 synergizes with ATF4 by reducing *Ocn* gene transcription and inducing *Esp* gene transcription, with the eventual result of reducing osteocalcin expression and promoting its carboxylation. Accordingly, osteoblast-specific FoxO1 deletion reduced osteoblast OST-PTP expression, increased osteocalcin and protected against obesity, diabetes and fatty liver (Rached JCI 2010, 46).

FoxO1 inhibits *Ocn* gene expression by interacting with the *Ocn* gene-promoting transcription factor Runx2 and suppressing its binding to its cognate site within the *Ocn* promoter region (Yang IBC 2011, 47)

Insulin and IGF-1 stimulate osteoblast differentiation and osteocalcin expression by relieving the suppression of Runx2 by Twist2 (46 Fulzele 2010). Insulin and IGF-1 antagonize FoxO1 activity by promoting its phosphorylation through the PI3K/AKT-dependent pathway: FoxO1 phosphorylation (P-FoxO1) results in its nuclear exclusion and inhibition of target gene expression (Yang IBC 2011, 47). FoxO1 inactivation favours Osteocalcin activity in a dual mode of action. On one hand, it down-regulates expression of *Esp* thereby promoting Osteocalcin decarboxylation. On the other hand, it reduces production of the anti-osteoclastogenic factor Osteoprotegerin (*Opg*), and promotes osteoclastogenesis and bone resorption (Ferron M., Cell, 2010;48). Through these feedback pathways, one at the transcriptional level with FoxO1 and the other at the hormonal level with osteocalcin, the skeleton and pancreas interact to tightly regulate energy metabolism and bone turnover.

Homocysteine inhibits osteoprotegerin by inducing FOXO1 loss through protein phosphatase 2A (PP2A) phosphorylation and enhances RANKL expression by activating JNK MAP kinase signalling pathway (62 Vijayan FRBM 2013).


Another important regulator of osteoblast differentiation and osteocalcin secretion is sympathetic nervous system (SNS), which inhibits osteoblast differentiation and ucOC formation. The clinical importance of sympathetic tone, which mediates part of the indirect effects of leptin on osteoblast activity, for bone health is suggested by the 24–32% reduction in the risk of fractures experienced by people receiving  $\beta$ -blockers emerged in several large studies

## **Figure 2. Endocrine connection between osteoblasts and adipocytes**


The transcriptional factor FoxO1 is also expressed in osteoblasts (OB). Osteoblast-specific FoxO1 deficiency is associated with an anabolic metabolism profile due to increased osteocalcin expression and decreased expression of *Esp*. In addition, osteocalcin may stimulate adipose tissue to secrete adiponectin, an insulin-sensitizing factor. Adipocytes (AD) affect bone and energetic metabolism by secreting leptin. In the CNS leptin stimulates the sympathetic nervous system (SNS) thereby activating the  $\beta$ 2-adrenergic receptor (Adr $\beta$ 2) in bone and subsequently

decreasing OB proliferation. Leptin also improves insulin sensitivity and this effect may be, at least in part, mediated by IGFBP2.

Osteocalcin bioactivity can be regulated in a bimodal mechanism of action. In the first mechanism osteocalcin activity is negatively regulated by another gene expressed in osteoblasts, *Esp*. Protein-tyrosine phosphatase (OST-PTP), the product of *Esp*, decreases osteocalcin bioactivity by favoring its carboxylation (2). In the second mechanism bone resorption induces a change in the pH that spontaneously decarboxylates and activates osteocalcin (3). Respective to the latter mechanism, we did not detect any increases in osteoclast function in *FoxO1osb*  $_{-/-};Atf4_{-/-}$  mice that would indicate an increase in bone resorption (Fig. 5G).



**Osteoblast signaling pathways involved in energy metabolism regulation.** Effects of insulin and sympathetic nervous system (SNS) on osteocalcin (OCN), osteotesticular protein tyrosine phosphatase (OST-PTP), and osteoprotegerin (OPG). Adrbeta2, beta2-adrenergic receptor; ATF4, activating transcription factor 4; InsR, insulin receptor. Adapted from Confavreux.<sup>22</sup>



**Insulin and bone resorption affect circulating uncarboxylated osteocalcin (Glu-OCN).**

Insulin binds its receptor (InsR), which reduces osteoprotegerin (OPG) expression, thus enhancing osteoclast formation and activity. During bone resorption, acidification of the extracellular compartment decarboxylates inactive osteocalcin (Gla-OCN) to Glu-OCN. Glu-OCN is then released into the blood stream to affect target tissues. OST-PTP, osteotesticular protein tyrosine phosphatase. Adapted from *Cell*,<sup>27</sup> with permission from Elsevier.

**Table 1. Effect of  $\beta$ -blockers on fracture risk<sup>12</sup>**

[Figures and tables index](#)

Study	Study design	Subjects	Fracture type	Hazard or odds ratio (95% CI)	Reference
SOF	Prospective cohort	8412 (13.1% users)	Hip	0.76 (0.58–0.99)	Reid <i>et al.</i> <sup>10</sup>
GPRD	Retrospective case-control	120,819 controls (17.6% users), 30,601 cases (16% users)	Any	0.77 (0.72–0.83)	Schlienger <i>et al.</i> <sup>11</sup>
			Hip	0.68 (0.52–0.89)	
Geelong Osteoporosis Study	Population-based case-control	775 controls (14.5% users), 569 cases (10.4% users)	Any	0.69 (0.49–0.96)	Pasco <i>et al.</i> <sup>9</sup>

Abbreviations: CI, confidence interval; GPRD, General Practice Research Database; SOF, Study of Osteoporotic Fractures.

**BOX 2. The RANKL-RANK-OPG system**

OPG regulates bone turnover through the RANKL-RANK system. The receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), a member of the TNF superfamily, is an osteoclast differentiation factor expressed by osteoblasts as a transmembrane protein; RANKL binds to its receptor RANK, which is expressed by both mature osteoclasts and osteoclasts progenitors, leading to osteoclast differentiation and activation and consequently bone resorption.

The RANKL–RANK interaction leads to the recruitment of TNF receptor-associated factors (TRAFs) to the intracellular domain of RANK, among which TRAF6 seems to have a central role for the osteoclasts resorptive activity. TRAFs recruitment activates many downstream targets, which lead to osteoclast differentiation (transcription factor NF- $\kappa$ B, p38, JNK mitogen-activated protein kinases -MAPKs) and survival (PI3K/Akt/mTOR signalling pathway, MAPK extracellular signal-related kinase - ERK).

RANKL seems to support osteoclast formation as a membrane-associated factor, while its role as a soluble form is still debatable: activated T cell, which have been found involved in the osteoclastogenesis in rheumatoid arthritis, produce membrane-anchored RANKL that is shedded by metalloprotease-disintegrin TNF $\alpha$  convertase (TACE) to form soluble RANKL (sRANKL). OPG produced by osteoblasts exerts osteoprotective effects by inhibiting the RANKL-RANK interaction, binding as a homodimer to the homotrimeric RANKL, thus preventing its binding to RANK and subsequent osteoclast activation.

Besides the regulation of bone turnover, the RANKL-RANK-OPG system affects the immune system. The interaction between T cell-derived RANKL with RANK on the surface of the dendritic cells (DC) enhances activation and survival of DC, T cell and monocytes/macrophages; OPG administration leads to a reduction in DC survival, suggesting that OPG may downregulate the immune response inhibiting the RANKL-RANK binding also on immune cells.


Both OPG and RANKL mRNAs are expressed in adipocytes, under the regulation of TNF-  $\alpha$ , insulin and Rosiglitazone. The elevation of RANKL by TNF $\alpha$  could stimulate angiogenesis in adipose tissue, while insulin and rosiglitazone suppress OPG: both these pathways lead to adipose tissue growth.

OPG exerts anti-apoptotic properties by acting as soluble receptor for TNF related activation induced ligand (TRAIL). TRAIL is produced by immune cells, such as monocytes, within the tumour microenvironment in response to interferon  $\alpha$  and  $\gamma$ . This cytokine activates tumor cell apoptotic signalling pathways through the death receptors DR4 and DR5: OPG binds to TRAIL thus preventing its interaction with the functional death receptors and allowing cells to escape apoptosis.

OPG can also promote endothelial cell survival. As non-malignant cell are unresponsive to TRAIL, the mechanism underlying OPG-mediated increase in endothelial cells survive remain to be identified.



**Figure 2. Osteoclast**



**Figure 1 Osteopontin molecular structure and interactions.**

Osteopontin binds to integrins, transmembrane and dimeric proteins consisting of  $\alpha$  and  $\beta$  subunits. It has several cell interacting domains that facilitate integrin binding in different cell types:

- an arginine-glycine-aspartic acid (RGD) cell binding sequence, which interacts with cell surface integrins  $\alpha\nu\beta3$ ,  $\alpha\nu\beta1$ ,  $\alpha\nu\beta5$  and  $\alpha8\beta1$ .
- A serine-valine-valinetyrosine-glutamate-leucine-arginine (SVVYGLR)-containing domain, located between the RGD sequence and the thrombin cleavage site, which interacts with  $\alpha9\beta1$ ,  $\alpha4\beta1$  and  $\alpha4\beta7$

- A ELVTDFDLPAT domain is also reported to bind to  $\alpha 4\beta 1$
- A calcium binding site and 2 heparin binding domains also exist: the heparin binding domains bind CD44 receptor.

Furthermore, OPN can be cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). *In vitro*, fragments generated by cleavage expose new active domains that may impart new activities.

## Figure 2. mechanisms regulating secretion and biological activity of osteocalcin

In osteoblasts, uncarboxylated osteocalcin (uc-OCN) undergoes posttranslational modification whereby three glutamic acid residues are carboxylated to form  $\gamma$ -carboxyglutamic acid residues (carboxylated osteocalcin, carboxy-OCN). In animal studies, the uncarboxylated form appeared to mediate the metabolic effects of osteocalcin (i.e. increased  $\beta$ -cell proliferation, insulin secretion, insulin sensitivity and adiponectin and adiponectin expression, while carboxy-OC has a lower metabolic bioactivity and higher affinity for hydroxyapatite and this is thought to be involved in bone extracellular matrix mineralization, although conclusive data in humans are lacking. The *Esp* gene, expressed only in osteoblasts, embryonic stem cells, and Sertoli cells, codes for the protein tyrosine phosphatase osteotesticular protein tyrosine phosphatase (OST-PTP), which induces osteocalcin  $\gamma$ -carboxylation in a vitamin K-dependent reaction, thereby reducing osteocalcin metabolic bioactivity.

The endocrine function of osteoblasts is regulated by 2 transcription factors, the Activating transcription factor 4 (ATF4) and the Forkhead transcription factor FoxO1. ATF4 belongs to the cAMP-responsive element-binding protein transcription factor family, is upregulated by sympathetic nervous system (SNS) activation and induces *Esp* and *Ocn* gene expression, with the eventual effect of promoting glucose intolerance and insulin resistance: consistently, osteoblast-specific ATF4 deletion enhanced glucose tolerance and insulin sensitivity (Kode JBC 2012, 48). The transcription factor FoxO1 synergizes with ATF4 by reducing *Ocn* gene transcription and inducing *Esp* gene transcription, with the eventual result of reducing osteocalcin expression and promoting its carboxylation. Accordingly, osteoblast-specific FoxO1 deletion reduced osteoblast OST-PTP expression, increased osteocalcin and protected against obesity, diabetes and fatty liver (Rached JCI 2010, 46).

FoxO1 inhibits *Ocn* gene expression by interacting with the *Ocn* gene-promoting transcription factor Runx2 and suppressing its binding to its cognate site within the *Ocn* promoter region (Yang IBC 2011, 47)

Insulin and IGF-1 stimulate osteoblast differentiation and osteocalcin expression by relieving the suppression of Runx2 by Twist2 (46 Fulzele 2010). Insulin and IGF-1 antagonize FoxO1 activity by promoting its phosphorylation through the PI3K/AKT-dependent pathway: FoxO1 phosphorylation (P-FoxO1) results in its nuclear exclusion and inhibition of target gene expression (Yang IBC 2011, 47). FoxO1 inactivation favours Osteocalcin activity in a dual mode of action. On one hand, it down-regulates expression of *Esp* thereby promoting Osteocalcin decarboxylation. On the other hand, it reduces production of the anti-osteoclastogenic factor Osteoprotegerin (*Opg*), and promotes osteoclastogenesis and bone resorption (Ferron M., Cell, 2010;48). Through these feedback pathways, one at the transcriptional level with FoxO1 and the other at the hormonal level with osteocalcin, the skeleton and pancreas interact to tightly regulate energy metabolism and bone turnover.

Homocysteine inhibits osteoprotegerin by inducing FOXO1 loss through protein phosphatase 2A (PP2A) phosphorylation and enhances RANKL expression by activating JNK MAP kinase signalling pathway (62 Vijayan FRBM 2013).

Another important regulator of osteoblast differentiation and osteocalcin secretion is sympathetic nervous system (SNS), which inhibits osteoblast differentiation and ucOC formation. The clinical importance of sympathetic tone, which mediates part of the indirect effects of leptin on osteoblast activity, for bone health is suggested by the 24–32% reduction in the risk of fractures experienced by people receiving  $\beta$ -blockers emerged in several large studies


## **Figure 2. Endocrine connection between osteoblasts and adipocytes**

The transcriptional factor FoxO1


is also expressed in osteoblasts (OB). Osteoblast-specific FoxO1 deficiency is associated with an anabolic metabolism profile due to increased osteocalcin expression and decreased expression of *Esp*. In addition, osteocalcin may stimulate adipose tissue to secrete adiponectin, an insulin-sensitizing factor. Adipocytes (AD) affect bone and energetic metabolism by secreting leptin. In the CNS leptin stimulates the sympathetic nervous system (SNS) thereby activating the  $\beta$ 2-adrenergic receptor (Adrb $\beta$ 2) in bone and subsequently

decreasing OB proliferation. Leptin also improves insulin sensitivity and this effect may be, at least in part, mediated by IGFBP2.

Osteocalcin bioactivity can be regulated in a bimodal mechanism of action. In the first mechanism osteocalcin activity is negatively regulated by another gene expressed in osteoblasts, *Esp*. Protein-tyrosine phosphatase (OST-PTP), the product of *Esp*, decreases osteocalcin bioactivity by favoring its carboxylation (2). In the second mechanism bone resorption induces a change in the pH that spontaneously decarboxylates and activates osteocalcin (3). Respective to the latter mechanism, we did not detect any increases in osteoclast function in *FoxO1osb*  $_{-/-};Atf4_{-/-}$  mice that would indicate an increase in bone resorption (Fig. 5G).



**Osteoblast signaling pathways involved in energy metabolism regulation.** Effects of insulin and sympathetic nervous system (SNS) on osteocalcin (OCN), osteotesticular protein tyrosine phosphatase (OST-PTP), and osteoprotegerin (OPG). Adrβ2, β2-adrenergic receptor; ATF4, activating transcription factor 4; InsR, insulin receptor. Adapted from Confavreux.<sup>22</sup>



**Insulin and bone resorption affect circulating uncarboxylated osteocalcin (Glu-OCN).**

Insulin binds its receptor (InsR), which reduces osteoprotegerin (OPG) expression, thus enhancing osteoclast formation and activity. During bone resorption, acidification of the extracellular compartment decarboxylates inactive osteocalcin (Gla-OCN) to Glu-OCN. Glu-OCN is then released into the blood stream to affect target tissues. OST-PTP, osteotesticular protein tyrosine phosphatase. Adapted from *Cell*,<sup>27</sup> with permission from Elsevier.

**Table 1. Effect of  $\beta$ -blockers on fracture risk<sup>12</sup>**

[Figures and tables index](#)

Study	Study design	Subjects	Fracture type	Hazard or odds ratio (95% CI)	Reference
SOF	Prospective cohort	8412 (13.1% users)	Hip	0.76 (0.58–0.99)	Reid <i>et al.</i> <sup>10</sup>
GPRD	Retrospective case-control	120,819 controls (17.6% users), 30,601 cases (16% users)	Any	0.77 (0.72–0.83)	Schlienger <i>et al.</i> <sup>11</sup>
			Hip	0.68 (0.52–0.89)	
Geelong Osteoporosis Study	Population-based case-control	775 controls (14.5% users), 569 cases (10.4% users)	Any	0.69 (0.49–0.96)	Pasco <i>et al.</i> <sup>9</sup>

Abbreviations: CI, confidence interval; GPRD, General Practice Research Database; SOF, Study of Osteoporotic Fractures.

**BOX 2. The RANKL-RANK-OPG system**

OPG regulates bone turnover through the RANKL-RANK system. The receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), a member of the TNF superfamily, is an osteoclast differentiation factor expressed by osteoblasts as a transmembrane protein; RANKL binds to its receptor RANK, which is expressed by both mature osteoclasts and osteoclasts progenitors, leading to osteoclast differentiation and activation and consequently bone resorption.

The RANKL–RANK interaction leads to the recruitment of TNF receptor-associated factors (TRAFs) to the intracellular domain of RANK, among which TRAF6 seems to have a central role for the osteoclasts resorptive activity. TRAFs recruitment activates many downstream targets, which lead to osteoclast differentiation (transcription factor NF- $\kappa$ B, p38, JNK mitogen-activated protein kinases -MAPKs) and survival (PI3K/Akt/mTOR signalling pathway, MAPK extracellular signal-related kinase - ERK).

RANKL seems to support osteoclast formation as a membrane-associated factor, while its role as a soluble form is still debatable: activated T cell, which have been found involved in the osteoclastogenesis in rheumatoid arthritis, produce membrane-anchored RANKL that is shedded by metalloprotease-disintegrin TNF $\alpha$  convertase (TACE) to form soluble RANKL (sRANKL). OPG produced by osteoblasts exerts osteoprotective effects by inhibiting the RANKL-RANK interaction, binding as a homodimer to the homotrimeric RANKL, thus preventing its binding to RANK and subsequent osteoclast activation.


Besides the regulation of bone turnover, the RANKL-RANK-OPG system affects the immune system. The interaction between T cell-derived RANKL with RANK on the surface of the dendritic cells (DC) enhances activation and survival of DC, T cell and monocytes/macrophages; OPG administration leads to a reduction in DC survival, suggesting that OPG may downregulate the immune response inhibiting the RANKL-RANK binding also on immune cells.

Both OPG and RANKL mRNAs are expressed in adipocytes, under the regulation of TNF-  $\alpha$ , insulin and Rosiglitazone. The elevation of RANKL by TNF $\alpha$  could stimulate angiogenesis in adipose tissue, while insulin and rosiglitazone suppress OPG: both these pathways lead to adipose tissue growth.

OPG exerts anti-apoptotic properties by acting as soluble receptor for TNF related activation induced ligand (TRAIL). TRAIL is produced by immune cells, such as monocytes, within the tumour microenvironment in response to interferon  $\alpha$  and  $\gamma$ . This cytokine activates tumor cell apoptotic signalling pathways through the death receptors DR4 and DR5: OPG binds to TRAIL thus preventing its interaction with the functional death receptors and allowing cells to escape apoptosis.

OPG can also promote endothelial cell survival. As non-malignant cell are unresponsive to TRAIL, the mechanism underlying OPG-mediated increase in endothelial cells survive remain to be identified.

Figure 2. Osteoclast





### **Figure 1 Osteopontin molecular structure and interactions.**

Osteopontin binds to integrins, transmembrane and dimeric proteins consisting of  $\alpha$  and  $\beta$  subunits. It has several cell interacting domains that facilitate integrin binding in different cell types:

- an arginine-glycine-aspartic acid (RGD) cell binding sequence, which interacts with cell surface integrins  $\alpha v\beta 3$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 5$  and  $\alpha 8\beta 1$ .
- A serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR)-containing domain, located between the RGD sequence and the thrombin cleavage site, which interacts with  $\alpha 9\beta 1$ ,  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$
- A ELVTDFDLPAT domain is also reported to bind to  $\alpha 4\beta 1$
- A calcium binding site and 2 heparin binding domains also exist: the heparin binding domains bind CD44 receptor.

Furthermore, OPN can be cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). *In vitro*, fragments generated by cleavage expose new active domains that may impart new activities.

## Figure 2. mechanisms regulating secretion and biological activity of osteocalcin

In osteoblasts, uncarboxylated osteocalcin (uc-OCN) undergoes posttranslational modification whereby three glutamic acid residues are carboxylated to form  $\gamma$ -carboxyglutamic acid residues (carboxylated osteocalcin, carboxy-OCN). In animal studies, the uncarboxylated form appeared to mediate the metabolic effects of osteocalcin (i.e. increased  $\beta$ -cell proliferation, insulin secretion, insulin sensitivity and adiponectin and adiponectin expression, while carboxy-OC has a lower metabolic bioactivity and higher affinity for hydroxyapatite and this is thought to be involved in bone extracellular matrix mineralization, although conclusive data in humans are lacking. The *Esp* gene, expressed only in osteoblasts, embryonic stem cells, and Sertoli cells, codes for the protein tyrosine phosphatase osteotesticular protein tyrosine phosphatase (OST-PTP), which induces osteocalcin  $\gamma$ -carboxylation in a vitamin K-dependent reaction, thereby reducing osteocalcin metabolic bioactivity.

The endocrine function of osteoblasts is regulated by 2 transcription factors, the Activating transcription factor 4 (ATF4) and the Forkhead transcription factor FoxO1. ATF4 belongs to the cAMP-responsive element-binding protein transcription factor family, is upregulated by sympathetic nervous system (SNS) activation and induces *Esp* and *Ocn* gene expression, with the eventual effect of promoting glucose intolerance and insulin resistance: consistently, osteoblast-specific ATF4 deletion enhanced glucose tolerance and insulin sensitivity (Kode JBC 2012, 48). The transcription factor FoxO1 synergizes with ATF4 by reducing *Ocn* gene transcription and inducing *Esp* gene transcription, with the eventual result of reducing osteocalcin expression and promoting its carboxylation. Accordingly, osteoblast-specific FoxO1 deletion reduced osteoblast OST-PTP expression, increased osteocalcin and protected against obesity, diabetes and fatty liver (Rached JCI 2010, 46).

FoxO1 inhibits *Ocn* gene expression by interacting with the *Ocn* gene-promoting transcription factor Runx2 and suppressing its binding to its cognate site within the *Ocn* promoter region (Yang IBC 2011, 47)

Insulin and IGF-1 stimulate osteoblast differentiation and osteocalcin expression by relieving the suppression of Runx2 by Twist2 (46 Fulzele 2010). Insulin and IGF-1 antagonize FoxO1 activity by promoting its phosphorylation through the PI3K/AKT-dependent pathway: FoxO1 phosphorylation (P-FoxO1) results in its nuclear exclusion and inhibition of target gene expression (Yang IBC 2011, 47). FoxO1 inactivation favours Osteocalcin activity in a dual mode of action. On one hand, it down-regulates expression of *Esp* thereby promoting Osteocalcin decarboxylation. On the other hand, it reduces production of the anti-osteoclastogenic factor Osteoprotegerin (*Opg*), and promotes osteoclastogenesis and bone resorption (Ferron M., Cell, 2010;48). Through these feedback pathways, one at the transcriptional level with FoxO1 and the other at the hormonal level with osteocalcin, the skeleton and pancreas interact to tightly regulate energy metabolism and bone turnover.

Homocysteine inhibits osteoprotegerin by inducing FOXO1 loss through protein phosphatase 2A (PP2A) phosphorylation and enhances RANKL expression by activating JNK MAP kinase signalling pathway (62 Vijayan FRBM 2013).


Another important regulator of osteoblast differentiation and osteocalcin secretion is sympathetic nervous system (SNS), which inhibits osteoblast differentiation and uOC formation. The clinical importance of sympathetic tone, which mediates part of the indirect effects of leptin on osteoblast activity, for bone health is suggested by the 24–32% reduction in the risk of fractures experienced by people receiving  $\beta$ -blockers emerged in several large studies

## **Figure 2. Endocrine connection between osteoblasts and adipocytes**


The transcriptional factor FoxO1 is also expressed in osteoblasts (OB). Osteoblast-specific FoxO1 deficiency is associated with an anabolic metabolism profile due to increased osteocalcin expression and decreased expression of *Esp*. In addition, osteocalcin may stimulate adipose tissue to secrete adiponectin, an insulin-sensitizing factor. Adipocytes (AD) affect bone and energetic metabolism by secreting leptin. In the CNS leptin stimulates the sympathetic nervous system (SNS) thereby activating the  $\beta$ 2-adrenergic receptor (Adrb $\beta$ 2) in bone and subsequently

decreasing OB proliferation. Leptin also improves insulin sensitivity and this effect may be, at least in part, mediated by IGFBP2.

Osteocalcin bioactivity can be regulated in a bimodal mechanism of action. In the first mechanism osteocalcin activity is negatively regulated by another gene expressed in osteoblasts, *Esp*. Protein-tyrosine phosphatase (OST-PTP), the product of *Esp*, decreases osteocalcin bioactivity by favoring its carboxylation (2). In the second mechanism bone resorption induces a change in the pH that spontaneously decarboxylates and activates osteocalcin (3). Respective to the latter mechanism, we did not detect any increases in osteoclast function in *FoxO1osb* *-/-*; *Atf4* *-/-* mice that would indicate an increase in bone resorption (Fig. 5G).



**Osteoblast signaling pathways involved in energy metabolism regulation.** Effects of insulin and sympathetic nervous system (SNS) on osteocalcin (OCN), osteotesticular protein tyrosine phosphatase (OST-PTP), and osteoprotegerin (OPG). Adrβ2, β2-adrenergic receptor; ATF4, activating transcription factor 4; InsR, insulin receptor. Adapted from Confavreux.<sup>22</sup>



**Insulin and bone resorption affect circulating uncarboxylated osteocalcin (Glu-OCN).** Insulin binds its receptor (InsR), which reduces osteoprotegerin (OPG) expression, thus enhancing osteoclast formation and activity. During bone resorption, acidification of the extracellular compartment decarboxylates inactive osteocalcin (Gla-OCN) to Glu-OCN. Glu-OCN is then released into the blood stream to affect target tissues. OST-PTP, osteotesticular protein tyrosine phosphatase. Adapted from *Cell*,<sup>27</sup> with permission from Elsevier.

**Table 1. Effect of  $\beta$ -blockers on fracture risk<sup>12</sup>**

[Figures and tables index](#)

Study	Study design	Subjects	Fracture type	Hazard or odds ratio (95% CI)	Reference
SOF	Prospective cohort	8412 (13.1% users)	Hip	0.76 (0.58–0.99)	Reid <i>et al.</i> <sup>10</sup>
GPRD	Retrospective case-control	120,819 controls (17.6% users), 30,601 cases (16% users)	Any	0.77 (0.72–0.83)	Schlienger <i>et al.</i> <sup>11</sup>
			Hip	0.68 (0.52–0.89)	
Geelong Osteoporosis Study	Population-based case-control	775 controls (14.5% users), 569 cases (10.4% users)	Any	0.69 (0.49–0.96)	Pasco <i>et al.</i> <sup>9</sup>

Abbreviations: CI, confidence interval; GPRD, General Practice Research Database; SOF, Study of Osteoporotic Fractures.

### **BOX 2. The RANKL-RANK-OPG system**

OPG regulates bone turnover through the RANKL-RANK system. The receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), a member of the TNF superfamily, is an osteoclast differentiation factor expressed by osteoblasts as a transmembrane protein; RANKL binds to its receptor RANK, which is expressed by both mature osteoclasts and osteoclasts progenitors, leading to osteoclast differentiation and activation and consequently bone resorption.

The RANKL–RANK interaction leads to the recruitment of TNF receptor-associated factors (TRAFs) to the intracellular domain of RANK, among which TRAF6 seems to have a central role for the osteoclasts resorptive activity. TRAFs recruitment activates many downstream targets, which lead to osteoclast differentiation (transcription factor NF- $\kappa$ B, p38, JNK mitogen-activated protein kinases -MAPKs) and survival (PI3K/Akt/mTOR signalling pathway, MAPK extracellular signal-related kinase - ERK).

RANKL seems to support osteoclast formation as a membrane-associated factor, while its role as a soluble form is still debatable: activated T cell, which have been found involved in the osteoclastogenesis in rheumatoid arthritis, produce membrane-anchored RANKL that is shedded by metalloprotease-disintegrin TNF $\alpha$  convertase (TACE) to form soluble RANKL (sRANKL). OPG produced by osteoblasts exerts osteoprotective effects by inhibiting the RANKL-RANK interaction, binding as a homodimer to the homotrimeric RANKL, thus preventing its binding to RANK and subsequent osteoclast activation.


Besides the regulation of bone turnover, the RANKL-RANK-OPG system affects the immune system. The interaction between T cell-derived RANKL with RANK on the surface of the dendritic cells (DC) enhances activation and survival of DC, T cell and monocytes/macrophages; OPG administration leads to a reduction in DC survival, suggesting that OPG may downregulate the immune response inhibiting the RANKL-RANK binding also on immune cells.

Both OPG and RANKL mRNAs are expressed in adipocytes, under the regulation of TNF-  $\alpha$ , insulin and Rosiglitazone. The elevation of RANKL by TNF $\alpha$  could stimulate angiogenesis in adipose tissue, while insulin and rosiglitazone suppress OPG: both these pathways lead to adipose tissue growth.

OPG exerts anti-apoptotic properties by acting as soluble receptor for TNF related activation induced ligand (TRAIL). TRAIL is produced by immune cells, such as monocytes, within the tumour microenvironment in response to interferon  $\alpha$  and  $\gamma$ . This cytokine activates tumor cell apoptotic signalling pathways through the death receptors DR4 and DR5: OPG binds to TRAIL thus preventing its interaction with the functional death receptors and allowing cells to escape apoptosis.

OPG can also promote endothelial cell survival. As non-malignant cell are unresponsive to TRAIL, the mechanism underlying OPG-mediated increase in endothelial cells survive remain to be identified.

Figure 2. Osteoclast



### **Figure 1 Osteopontin molecular structure and interactions.**

Osteopontin binds to integrins, transmembrane and dimeric proteins consisting of  $\alpha$  and  $\beta$  subunits. It has several cell interacting domains that facilitate integrin binding in different cell types:

- an arginine-glycine-aspartic acid (RGD) cell binding sequence, which interacts with cell surface integrins  $\alpha v\beta 3$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 5$  and  $\alpha 8\beta 1$ .
- A serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR)-containing domain, located between the RGD sequence and the thrombin cleavage site, which interacts with  $\alpha 9\beta 1$ ,  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$
- A ELVTDFDLPAT domain is also reported to bind to  $\alpha 4\beta 1$
- A calcium binding site and 2 heparin binding domains also exist: the heparin binding domains bind CD44 receptor.

Furthermore, OPN can be cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). *In vitro*, fragments generated by cleavage expose new active domains that may impart new activities.



## Figure 2. mechanisms regulating secretion and biological activity of osteocalcin

In osteoblasts, uncarboxylated osteocalcin (uc-OCN) undergoes posttranslational modification whereby three glutamic acid residues are carboxylated to form  $\gamma$ -carboxyglutamic acid residues (carboxylated osteocalcin, carboxy-OCN). In animal studies, the uncarboxylated form appeared to mediate the metabolic effects of osteocalcin (i.e. increased  $\beta$ -cell proliferation, insulin secretion, insulin sensitivity and adiponectin and adiponectin expression, while carboxy-OC has a lower metabolic bioactivity and higher affinity for hydroxyapatite and this is thought to be involved in bone extracellular matrix mineralization, although conclusive data in humans are lacking. The *Esp* gene, expressed only in osteoblasts, embryonic stem cells, and Sertoli cells, codes for the protein tyrosine phosphatase osteotesticular protein tyrosine phosphatase (OST-PTP), which induces osteocalcin  $\gamma$ -carboxylation in a vitamin K-dependent reaction, thereby reducing osteocalcin metabolic bioactivity.

The endocrine function of osteoblasts is regulated by 2 transcription factors, the Activating transcription factor 4 (ATF4) and the Forkhead transcription factor FoxO1. ATF4 belongs to the cAMP-responsive element-binding protein transcription factor family, is upregulated by sympathetic nervous system (SNS) activation and induces *Esp* and *Ocn* gene expression, with the eventual effect of promoting glucose intolerance and insulin resistance: consistently, osteoblast-specific ATF4 deletion enhanced glucose tolerance and insulin sensitivity (Kode JBC 2012, 48). The transcription factor FoxO1 synergizes with ATF4 by reducing *Ocn* gene transcription and inducing *Esp* gene transcription, with the eventual result of reducing osteocalcin expression and promoting its carboxylation. Accordingly, osteoblast-specific FoxO1 deletion reduced osteoblast OST-PTP expression, increased osteocalcin and protected against obesity, diabetes and fatty liver (Rached JCI 2010, 46).

FoxO1 inhibits *Ocn* gene expression by interacting with the *Ocn* gene-promoting transcription factor Runx2 and suppressing its binding to its cognate site within the *Ocn* promoter region (Yang IBC 2011, 47)

Insulin and IGF-1 stimulate osteoblast differentiation and osteocalcin expression by relieving the suppression of Runx2 by Twist2 (46 Fulzele 2010). Insulin and IGF-1 antagonize FoxO1 activity by promoting its phosphorylation through the PI3K/AKT-dependent pathway: FoxO1 phosphorylation (P-FoxO1) results in its nuclear exclusion and inhibition of target gene expression (Yang IBC 2011, 47). FoxO1 inactivation favours Osteocalcin activity in a dual mode of action. On one hand, it down-regulates expression of *Esp* thereby promoting Osteocalcin decarboxylation. On the other hand, it reduces production of the anti-osteoclastogenic factor Osteoprotegerin (*Opg*), and promotes osteoclastogenesis and bone resorption (Ferron M., Cell, 2010;48). Through these feedback pathways, one at the transcriptional level with FoxO1 and the other at the hormonal level with osteocalcin, the skeleton and pancreas interact to tightly regulate energy metabolism and bone turnover.

Homocysteine inhibits osteoprotegerin by inducing FOXO1 loss through protein phosphatase 2A (PP2A) phosphorylation and enhances RANKL expression by activating JNK MAP kinase signalling pathway (62 Vijayan FRBM 2013).


Another important regulator of osteoblast differentiation and osteocalcin secretion is sympathetic nervous system (SNS), which inhibits osteoblast differentiation and ucOC formation. The clinical importance of sympathetic tone, which mediates part of the indirect effects of leptin on osteoblast activity, for bone health is suggested by the 24–32% reduction in the risk of fractures experienced by people receiving  $\beta$ -blockers emerged in several large studies

## **Figure 2. Endocrine connection between osteoblasts and adipocytes**

The transcriptional factor FoxO1 is also expressed in osteoblasts (OB). Osteoblast-specific FoxO1 deficiency is associated with an anabolic metabolism profile due to increased osteocalcin expression and decreased expression of *Esp*. In addition, osteocalcin may stimulate adipose tissue to secrete adiponectin, an insulin-sensitizing factor. Adipocytes (AD) affect bone and energetic metabolism by secreting leptin. In the CNS leptin stimulates the sympathetic nervous system (SNS) thereby activating the  $\beta$ 2-adrenergic receptor (Adr $\beta$ 2) in bone and subsequently


decreasing OB proliferation. Leptin also improves insulin sensitivity and this effect may be, at least in part, mediated by IGFBP2.

Osteocalcin bioactivity can be regulated in a bimodal mechanism of action. In the first mechanism osteocalcin activity is negatively regulated by another gene expressed in osteoblasts, *Esp*. Protein-tyrosine phosphatase (OST-PTP), the product of *Esp*, decreases osteocalcin bioactivity by favoring its carboxylation (2). In the second mechanism bone resorption induces a change in the pH that spontaneously decarboxylates and activates osteocalcin (3). Respective to the latter mechanism, we did not detect any increases in osteoclast function in *FoxO1osb* *-/-*; *Atf4* *-/-* mice that would indicate an increase in bone resorption (Fig. 5G).



**Osteoblast signaling pathways involved in energy metabolism regulation.** Effects of insulin and sympathetic nervous system (SNS) on osteocalcin (OCN), osteotesticular protein tyrosine phosphatase (OST-PTP), and osteoprotegerin (OPG). Adrβ2, β2-adrenergic receptor; ATF4, activating transcription factor 4; InsR, insulin receptor. Adapted from Confavreux.<sup>22</sup>

[Next figure](#) | [Previous figure](#) | [Figures and tables index](#)



**Insulin and bone resorption affect circulating uncarboxylated osteocalcin (Glu-OCN).** Insulin binds its receptor (InsR), which reduces osteoprotegerin (OPG) expression, thus enhancing osteoclast formation and activity. During bone resorption, acidification of the extracellular compartment decarboxylates inactive osteocalcin (Gla-OCN) to Glu-OCN. Glu-OCN is then released into the blood stream to affect target tissues. OST-PTP, osteotesticular protein tyrosine phosphatase. Adapted from *Cell*,<sup>27</sup> with permission from Elsevier.

**Table 1. Effect of  $\beta$ -blockers on fracture risk<sup>12</sup>**

[Figures and tables index](#)

Study	Study design	Subjects	Fracture type	Hazard or odds ratio (95% CI)	Reference
SOF	Prospective cohort	8412 (13.1% users)	Hip	0.76 (0.58–0.99)	Reid <i>et al.</i> <sup>10</sup>
GPRD	Retrospective case-control	120,819 controls (17.6% users), 30,601 cases (16% users)	Any	0.77 (0.72–0.83)	Schlienger <i>et al.</i> <sup>11</sup>
			Hip	0.68 (0.52–0.89)	
Geelong Osteoporosis Study	Population-based case-control	775 controls (14.5% users), 569 cases (10.4% users)	Any	0.69 (0.49–0.96)	Pasco <i>et al.</i> <sup>9</sup>

Abbreviations: CI, confidence interval; GPRD, General Practice Research Database; SOF, Study of Osteoporotic Fractures.

### **BOX 2. The RANKL-RANK-OPG system**

OPG regulates bone turnover through the RANKL-RANK system. The receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), a member of the TNF superfamily, is an osteoclast differentiation factor expressed by osteoblasts as a transmembrane protein; RANKL binds to its receptor RANK, which is expressed by both mature osteoclasts and osteoclasts progenitors, leading to osteoclast differentiation and activation and consequently bone resorption.

The RANKL–RANK interaction leads to the recruitment of TNF receptor-associated factors (TRAFs) to the intracellular domain of RANK, among which TRAF6 seems to have a central role for the osteoclasts resorptive activity. TRAFs recruitment activates many downstream targets, which lead to osteoclast differentiation (transcription factor NF- $\kappa$ B, p38, JNK mitogen-activated protein kinases -MAPKs) and survival (PI3K/Akt/mTOR signalling pathway, MAPK extracellular signal-related kinase - ERK).

RANKL seems to support osteoclast formation as a membrane-associated factor, while its role as a soluble form is still debatable: activated T cell, which have been found involved in the osteoclastogenesis in rheumatoid arthritis, produce membrane-anchored RANKL that is shedded by metalloprotease-disintegrin TNF $\alpha$  convertase (TACE) to form soluble RANKL (sRANKL).

OPG produced by osteoblasts exerts osteoprotective effects by inhibiting the RANKL-RANK interaction, binding as a homodimer to the homotrimeric RANKL, thus preventing its binding to RANK and subsequent osteoclast activation.


Besides the regulation of bone turnover, the RANKL-RANK-OPG system affects the immune system. The interaction between T cell-derived RANKL with RANK on the surface of the dendritic cells (DC) enhances activation and survival of DC, T cell and monocytes/macrophages; OPG administration leads to a reduction in DC survival, suggesting that OPG may downregulate the immune response inhibiting the RANKL-RANK binding also on immune cells.

Both OPG and RANKL mRNAs are expressed in adipocytes, under the regulation of TNF-  $\alpha$ , insulin and Rosiglitazone. The elevation of RANKL by TNF $\alpha$  could stimulate angiogenesis in adipose tissue, while insulin and rosiglitazone suppress OPG: both these pathways lead to adipose tissue growth.

OPG exerts anti-apoptotic properties by acting as soluble receptor for TNF related activation induced ligand (TRAIL). TRAIL is produced by immune cells, such as monocytes, within the tumour microenvironment in response to interferon  $\alpha$  and  $\gamma$  . This cytokine activates tumor cell apoptotic signalling pathways through the death receptors DR4 and DR5: OPG binds to TRAIL thus preventing its interaction with the functional death receptors and allowing cells to escape apoptosis.

OPG can also promote endothelial cell survival. As non-malignant cell are unresponsive to TRAIL, the mechanism underlying OPG-mediated increase in endothelial cells survive remain to be identified.

Figure 2. Osteoclast



### **Figure 1 Osteopontin molecular structure and interactions.**

Osteopontin binds to integrins, transmembrane and dimeric proteins consisting of  $\alpha$  and  $\beta$  subunits. It has several cell interacting domains that facilitate integrin binding in different cell types:

- an arginine-glycine-aspartic acid (RGD) cell binding sequence, which interacts with cell surface integrins  $\alpha v\beta 3$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 5$  and  $\alpha 8\beta 1$ .
- A serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR)-containing domain, located between the RGD sequence and the thrombin cleavage site, which interacts with  $\alpha 9\beta 1$ ,  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$
- A ELVTDFDLPAT domain is also reported to bind to  $\alpha 4\beta 1$
- A calcium binding site and 2 heparin binding domains also exist: the heparin binding domains bind CD44 receptor.

Furthermore, OPN can be cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). *In vitro*, fragments generated by cleavage expose new active domains that may impart new activities.

## Figure 2. mechanisms regulating secretion and biological activity of osteocalcin

In osteoblasts, uncarboxylated osteocalcin (uc-OCN) undergoes posttranslational modification whereby three glutamic acid residues are carboxylated to form  $\gamma$ -carboxyglutamic acid residues (carboxylated osteocalcin, carboxy-OCN). In animal studies, the uncarboxylated form appeared to mediate the metabolic effects of osteocalcin (i.e. increased  $\beta$ -cell proliferation, insulin secretion, insulin sensitivity and adiponectin and adiponectin expression, while carboxy-OC has a lower metabolic bioactivity and higher affinity for hydroxyapatite and this is thought to be involved in bone extracellular matrix mineralization, although conclusive data in humans are lacking. The *Esp* gene, expressed only in osteoblasts, embryonic stem cells, and Sertoli cells, codes for the protein tyrosine phosphatase osteotesticular protein tyrosine phosphatase (OST-PTP), which induces osteocalcin  $\gamma$ -carboxylation in a vitamin K-dependent reaction, thereby reducing osteocalcin metabolic bioactivity.

The endocrine function of osteoblasts is regulated by 2 transcription factors, the Activating transcription factor 4 (ATF4) and the Forkhead transcription factor FoxO1. ATF4 belongs to the cAMP-responsive element-binding protein transcription factor family, is upregulated by sympathetic nervous system (SNS) activation and induces *Esp* and *Ocn* gene expression, with the eventual effect of promoting glucose intolerance and insulin resistance: consistently, osteoblast-specific ATF4 deletion enhanced glucose tolerance and insulin sensitivity (Kode JBC 2012, 48). The transcription factor FoxO1 synergizes with ATF4 by reducing *Ocn* gene transcription and inducing *Esp* gene transcription, with the eventual result of reducing osteocalcin expression and promoting its carboxylation. Accordingly, osteoblast-specific FoxO1 deletion reduced osteoblast OST-PTP expression, increased osteocalcin and protected against obesity, diabetes and fatty liver (Rached JCI 2010, 46).

FoxO1 inhibits *Ocn* gene expression by interacting with the *Ocn* gene-promoting transcription factor Runx2 and suppressing its binding to its cognate site within the *Ocn* promoter region (Yang IBC 2011, 47)



Insulin and IGF-1 stimulate osteoblast differentiation and osteocalcin expression by relieving the suppression of Runx2 by Twist2 (46 Fulzele 2010). Insulin and IGF-1 antagonize FoxO1 activity by promoting its phosphorylation through the PI3K/AKT-dependent pathway: FoxO1 phosphorylation (P-FoxO1) results in its nuclear exclusion and inhibition of target gene expression (Yang IBC 2011, 47). FoxO1 inactivation favours Osteocalcin activity in a dual mode of action. On one hand, it down-regulates expression of *Esp* thereby promoting Osteocalcin decarboxylation. On the other hand, it reduces production of the anti-osteoclastogenic factor Osteoprotegerin (*Opg*), and promotes osteoclastogenesis and bone resorption (Ferron M., Cell, 2010;48). Through these feedback pathways, one at the transcriptional level with FoxO1 and the other at the hormonal level with osteocalcin, the skeleton and pancreas interact to tightly regulate energy metabolism and bone turnover.

Homocysteine inhibits osteoprotegerin by inducing FOXO1 loss through protein phosphatase 2A (PP2A) phosphorylation and enhances RANKL expression by activating JNK MAP kinase signalling pathway (62 Vijayan FRBM 2013).


Another important regulator of osteoblast differentiation and osteocalcin secretion is sympathetic nervous system (SNS), which inhibits osteoblast differentiation and uOC formation. The clinical importance of sympathetic tone, which mediates part of the indirect effects of leptin on osteoblast activity, for bone health is suggested by the 24–32% reduction in the risk of fractures experienced by people receiving  $\beta$ -blockers emerged in several large studies

## **Figure 2. Endocrine connection between osteoblasts and adipocytes**

The transcriptional factor FoxO1 is also expressed in osteoblasts (OB). Osteoblast-specific FoxO1 deficiency is associated with an anabolic metabolism profile due to increased osteocalcin expression and decreased expression of *Esp*. In addition, osteocalcin may stimulate adipose tissue to secrete adiponectin, an insulin-sensitizing factor. Adipocytes (AD) affect bone and energetic metabolism by secreting leptin. In the CNS leptin stimulates the sympathetic nervous system (SNS) thereby activating the  $\beta$ 2-adrenergic receptor (Adrb2) in bone and subsequently


decreasing OB proliferation. Leptin also improves insulin sensitivity and this effect may be, at least in part, mediated by IGFBP2.

Osteocalcin bioactivity can be regulated in a bimodal mechanism of action. In the first mechanism osteocalcin activity is negatively regulated by another gene expressed in osteoblasts, *Esp*. Protein-tyrosine phosphatase (OST-PTP), the product of *Esp*, decreases osteocalcin bioactivity by favoring its carboxylation (2). In the second mechanism bone resorption induces a change in the pH that spontaneously decarboxylates and activates osteocalcin (3). Respective to the latter mechanism, we did not detect any increases in osteoclast function in *FoxO1osb* *-/-*; *Atf4* *-/-* mice that would indicate an increase in bone resorption (Fig. 5G).



**Osteoblast signaling pathways involved in energy metabolism regulation.** Effects of insulin and sympathetic nervous system (SNS) on osteocalcin (OCN), osteotesticular protein tyrosine phosphatase (OST-PTP), and osteoprotegerin (OPG). Adrβ2, β2-adrenergic receptor; ATF4, activating transcription factor 4; InsR, insulin receptor. Adapted from Confavreux.<sup>22</sup>

[Next figure](#) | [Previous figure](#) | [Figures and tables index](#)



**Insulin and bone resorption affect circulating uncarboxylated osteocalcin (Glu-OCN).**

Insulin binds its receptor (InsR), which reduces osteoprotegerin (OPG) expression, thus enhancing osteoclast formation and activity. During bone resorption, acidification of the extracellular compartment decarboxylates inactive osteocalcin (Gla-OCN) to Glu-OCN. Glu-OCN is then released into the blood stream to affect target tissues. OST-PTP, osteotesticular protein tyrosine phosphatase. Adapted from *Cell*,<sup>27</sup> with permission from Elsevier.

**Table 1. Effect of  $\beta$ -blockers on fracture risk<sup>12</sup>**

[Figures and tables index](#)

Study	Study design	Subjects	Fracture type	Hazard or odds ratio (95% CI)	Reference
SOF	Prospective cohort	8412 (13.1% users)	Hip	0.76 (0.58–0.99)	Reid <i>et al.</i> <sup>10</sup>
GPRD	Retrospective case-control	120,819 controls (17.6% users), 30,601 cases (16% users)	Any	0.77 (0.72–0.83)	Schlienger <i>et al.</i> <sup>11</sup>
			Hip	0.68 (0.52–0.89)	
Geelong Osteoporosis Study	Population-based case-control	775 controls (14.5% users), 569 cases (10.4% users)	Any	0.69 (0.49–0.96)	Pasco <i>et al.</i> <sup>9</sup>

Abbreviations: CI, confidence interval; GPRD, General Practice Research Database; SOF, Study of Osteoporotic Fractures.

**BOX 2. The RANKL-RANK-OPG system**

OPG regulates bone turnover through the RANKL-RANK system. The receptor activator of nuclear factor- $\kappa$ B ligand (RANKL), a member of the TNF superfamily, is an osteoclast differentiation factor expressed by osteoblasts as a transmembrane protein; RANKL binds to its receptor RANK, which is expressed by both mature osteoclasts and osteoclasts progenitors, leading to osteoclast differentiation and activation and consequently bone resorption.

The RANKL–RANK interaction leads to the recruitment of TNF receptor-associated factors (TRAFs) to the intracellular domain of RANK, among which TRAF6 seems to have a central role for the osteoclasts resorptive activity. TRAFs recruitment activates many downstream targets, which lead to osteoclast differentiation (transcription factor NF- $\kappa$ B, p38, JNK mitogen-activated protein kinases -MAPKs) and survival (PI3K/Akt/mTOR signalling pathway, MAPK extracellular signal-related kinase - ERK).

RANKL seems to support osteoclast formation as a membrane-associated factor, while its role as a soluble form is still debatable: activated T cell, which have been found involved in the osteoclastogenesis in rheumatoid arthritis, produce membrane-anchored RANKL that is shedded by metalloprotease-disintegrin TNF $\alpha$  convertase (TACE) to form soluble RANKL (sRANKL).

OPG produced by osteoblasts exerts osteoprotective effects by inhibiting the RANKL-RANK interaction, binding as a homodimer to the homotrimeric RANKL, thus preventing its binding to RANK and subsequent osteoclast activation.


Besides the regulation of bone turnover, the RANKL-RANK-OPG system affects the immune system. The interaction between T cell-derived RANKL with RANK on the surface of the dendritic cells (DC) enhances activation and survival of DC, T cell and monocytes/macrophages; OPG administration leads to a reduction in DC survival, suggesting that OPG may downregulate the immune response inhibiting the RANKL-RANK binding also on immune cells.

Both OPG and RANKL mRNAs are expressed in adipocytes, under the regulation of TNF-  $\alpha$ , insulin and Rosiglitazone. The elevation of RANKL by TNF $\alpha$  could stimulate angiogenesis in adipose tissue, while insulin and rosiglitazone suppress OPG: both these pathways lead to adipose tissue growth.

OPG exerts anti-apoptotic properties by acting as soluble receptor for TNF related activation induced ligand (TRAIL). TRAIL is produced by immune cells, such as monocytes, within the tumour microenvironment in response to interferon  $\alpha$  and  $\gamma$  . This cytokine activates tumor cell apoptotic signalling pathways through the death receptors DR4 and DR5: OPG binds to TRAIL thus preventing its interaction with the functional death receptors and allowing cells to escape apoptosis.

OPG can also promote endothelial cell survival. As non-malignant cell are unresponsive to TRAIL, the mechanism underlying OPG-mediated increase in endothelial cells survive remain to be identified.

Figure 2. Osteoclast



### **Figure 1 Osteopontin molecular structure and interactions.**

Osteopontin binds to integrins, transmembrane and dimeric proteins consisting of  $\alpha$  and  $\beta$  subunits. It has several cell interacting domains that facilitate integrin binding in different cell types:

- an arginine-glycine-aspartic acid (RGD) cell binding sequence, which interacts with cell surface integrins  $\alpha v\beta 3$ ,  $\alpha v\beta 1$ ,  $\alpha v\beta 5$  and  $\alpha 8\beta 1$ .
- A serine-valine-valine-tyrosine-glutamate-leucine-arginine (SVVYGLR)-containing domain, located between the RGD sequence and the thrombin cleavage site, which interacts with  $\alpha 9\beta 1$ ,  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$
- A ELVTDFDLPAT domain is also reported to bind to  $\alpha 4\beta 1$
- A calcium binding site and 2 heparin binding domains also exist: the heparin binding domains bind CD44 receptor.

Furthermore, OPN can be cleaved by at least 2 classes of proteases: thrombin and matrix-metalloproteases (MMPs). *In vitro*, fragments generated by cleavage expose new active domains that may impart new activities.

**Table 1. Main mediators of interaction between the liver, adipose tissue and the bone**

<b>Osteopontin</b>					
<b>Secreting cells</b>	<b>Modulators of secretion</b>	<b>Target cell</b>	<b>Cellular mechanism</b>	<b>Biological effect</b>	<b>Ref.</b>
activated T-helper 1 and macrophages, NKT cells, osteoclast, SMC, endothelial cell, hepatocyte, hepatic stellate cells, adipocytes	<b>Stimulators</b> PTH; hedgehog signalling pathway; reactive oxygen species; NR4A2; Wnt/ $\beta$ -catenin signalling; Akt; EGF  <b>Inhibitors</b> PPAR- $\gamma$ ; miRNA-181a	Hepatocytes	↓ STAT3 activation → ↑ GSK-3 $\beta$ expression → ↑ gluconeogenic enzymes PEPCCK and G6P  ↑ FOXO1 expression → ↑ gluconeogenesis, ↓ IRS-2 phosphorylation  ↓ secretion of anti-inflammatory, insulin-sensitizing cytokine IL-10  ↑ SREBP-1c expression → ↑ <i>de novo</i> lipogenesis	↑ hepatic insulin resistance and inflammation  ↑ hepatic steatosis	[10] [18] [19] [22]  [19] [20] [25]
		Circulating NKT cells	↑ recruitment to the liver → ↑ activation of fibrogenesis	↑ hepatic fibrosis	[15]
		Hepatic stellate cells	↑ $\alpha$ v $\beta$ 3 integrin-mediated PI3-K/pAkt/NF $\kappa$ B pathway activation → ↑ proliferation, collagen I deposition, TGF- $\beta$ 1 receptor expression  ↓ extracellular MMP-13 secretion → ↓ collagen-I resorption	↑ hepatic fibrosis	[25]  [25] [32]
		Circulating monocytes	↑ JNK1/2 activation → ↑ monocyte adhesion, migration, differentiation, phagocytosis and secretion of proinflammatory cytokines TNF- $\alpha$ , MCP-1, IL-1, IL-6	↑ adipose tissue and hepatic macrophage infiltration	[12] [16] [17] [18]

		Adipocytes	<p>↑ JNK1/2 and ERK2 activation → ↑ insulin resistance, ↓ adiponectin secretion, ↑ IL-6 secretion</p> <p>↔ NF-κB pathway (unaffected)</p>	<p>and inflammation</p> <p>↑ adipose tissue and hepatic insulin resistance</p>	[19]
		HCC	<p>↑ PI3-K/Akt and HIF-1 pathway activation → ↑ NF-κB pathway activation</p> <p>↑ MMP-2/-7/-9 and Upa expression → ↑ ECM degradation</p> <p>↑ VEGF expression → ↑ angiogenesis</p>	<p>pro-, survival, anti-apoptosis and proliferation</p> <p>↑ tumor invasion and metastasis</p>	[26] [27] [30]
		Bone marrow multipotent stromal cells (BMSC)	OPN mediates high-fat diet-induced differentiation of BMSCs toward adipocyte and away from osteoblast cell line	↓ bone deposition	[16]
		Osteoclast	<p>↑ surface CD44 expression → ↑ motility</p> <p>↑ attachment of osteoclast to bone matrix via the αvβ3 integrin receptor in the sealing zone of resorptive pit</p>	↑ bone resorption	[16]

### Osteocalcin

Secreting cells	Modulators of secretion	Target cell	Cellular mechanism	Biological effect	Ref.
Osteoblast	Stimulators Insulin	Pancreatic β-cell	<p>↑ intracellular cAMP → ↑ ERK activation →</p> <p>↑ β-cell viability and function</p>	Preserved insulin	[55]



	<b>Inhibitors</b> Twist2; FoxO1; ATF4; ER stress			secretion	
		Enteroendocrine L-cells	↑ GLP-1 secretion	↑ insulin secretion	[46] [47] [50] [51] [56]
		Adipocyte	↑ adiponectin expression	↑ insulin sensitivity in muscle, liver, adipose tissue  ↓ hepatic steatosis and inflammation	[44]
		Adipocyte, hepatocyte, myocyte	↑ PI3-K/Akt pathway activation → ↑ NF-κB pathway activation  ↓ phosphorylation of PERK, eIF2α, and IRE-1α and the expression of ATF6β → ↓ ER stress response.  ↑ UCP-1 and PGC-1α → ↑ mitochondrial biogenesis and function in adipocytes.  ↑ mitochondrial number and mass in myocytes.	↑ energy expenditure → ↓ fat content in adipose tissue, liver and skeletal muscle  ↑ insulin sensitivity	[51]
		Bone matrix	Carboxylated osteocalcin binds hydroxyapatite	Uncertain effects on bone formation	[52]

**Receptor activator of nuclear factor-κB ligand (RANKL)**

Secreting cells	Modulators of secretion	Target cell	Cellular mechanism	Biological effect	Ref.
Osteoblast, T cells, adipocyte	<b>Stimulators</b> Adiponectin ; PPAR- $\gamma$ ; IL-1 $\beta$ ; TNF- $\alpha$ ; Homocysteine ;  <b>Inhibitors</b> 17 $\beta$ -estradiol; PPAR $\beta/\delta$ ; LXRs;	Osteoclast	RANK activation $\rightarrow$ $\uparrow$ Akt1 activation $\rightarrow$ $\uparrow$ osteoclast proliferation and activation  RANK activation $\rightarrow$ $\uparrow$ TRAF6-mediated NF- $\kappa$ B pathway activation $\rightarrow$ $\uparrow$ osteoclast proliferation and activation	$\uparrow$ bone resorption	[59] [61] [63] [64]
		dendritic cells (DC) , T cells, monocytes/macrophages	$\uparrow$ proliferation, activation and survival	$\uparrow$ immune function and inflammation	[62] [65] [66]
		hepatocytes	$\uparrow$ NF- $\kappa$ B pathway activation $\rightarrow$ $\uparrow$ hepatocyte proinflammatory pathway activation	$\uparrow$ hepatic insulin resistance and inflammation	[77]

### Osteoprotegerin

Secreting cells	Modulators of secretion	Target cell	Cellular mechanism	Biological effect	Ref.
Osteoblast, T cell, adipocyte, endothelial cell	<b>Stimulators</b> 17 $\beta$ -estradiol;  IL-1 $\beta$ ;	Osteoclast	<a href="#">decoy receptor for RANKL</a> $\rightarrow$ $\downarrow$ RANKL binding to osteoclast RANK $\rightarrow$ $\downarrow$ osteoclast proliferation and activation	$\downarrow$ bone resorption	[59]
		dendritic cell (DC) ,	$\downarrow$ proliferation, activation and survival	$\downarrow$ immune function and	[61] [62]

	TNF- $\alpha$ ; Insulin ; PPAR $\beta/\delta$ ; LXRs;	T cell, monocyte/m acrophage		inflammation	[64] [65] [66]
	<b>Inhibitors</b> Adiponectin ; Homocysteine; PPAR- $\gamma$	Hepatocyte	interaction with TRAIL $\rightarrow$ $\downarrow$ apoptosis activation	$\downarrow$ liver injury	[63] [64]

## Fetuin-A

Secreting cells	Modulators of secretion	Target cell	Cellular mechanism	Biological effect	Ref.
hepatocyte	<b>Stimulators</b> ER stress ; ERK1/2	Hepatocyte, miocyte	$\downarrow$ tyrosine kinase and IRS-1 autophosphorylation $\rightarrow$ $\downarrow$ insulin receptor tyrosine kinase activity	$\uparrow$ muscle and hepatic insulin resistance	[78] [90]
		Adipocyte	$\downarrow$ adiponectin secretion  $\uparrow$ interaction of circulating FFA with TLR4 $\rightarrow$ $\uparrow$ FFA-induced proinflammatory adipokine secretion	$\uparrow$ adipose tissue insulin resistance and inflammation	[80] [91]
		Bone and extracellular matrix	Complexation with calcium and phosphate to form stable colloidal mineral-protein spheres(calciprotein particles, CPPs).	Modulation of bone mineralization and ectopic calcification of soft tissues	[95] [96] [97]

## Leptin

Secreting cells	Modulators of secretion	Target cell	Cellular mechanism	Biological effect	Ref.
Mature adipocyte	<b>Stimulators</b> Adipocyte size;	Hypothalam ic arcuate nucleus	$\uparrow$ JAK2/STAT3 pathway $\rightarrow$ $\downarrow$ neuropeptide Y (NPY) and $\uparrow$ POMC synthesis	$\downarrow$ food intake	[101] ]

<p>Feeding; Glucocorticoids; Glucose; Insulin;</p> <p><b>Inhibitors</b> Fasting; Exercise; Cold exposure</p>	<p>Miocyte, hepatocyte</p>	<p>↓ malonyl-CoA synthesis → ↑ CPT I activity → mitochondrial FFA oxidation.</p> <p>↑ AMPK activation → ↑ FFA β-oxidation and glycolysis.</p> <p>↓ SREBP-1c expression → ↓ <i>de novo</i> lipogenesis.</p> <p>↑ hepatic vagal tone → ↓ PEPCK and G6P → ↓ gluconeogenesis.</p> <p>↑ Tg incorporation into VLDL particles → ↑ hepatic Tg secretion.</p> <p>↓ hepatic lipoprotein lipase activity → ↓ hepatic Tg uptake from plasma</p> <p>↑ insulin-like growth factor binding protein(IGFBP)-2 secretion</p>	<p>↓ muscle and hepatic triglyceride content</p> <p>↑ insulin sensitivity</p> <p>↑ hepatic insulin sensitivity</p> <p>↑ osteoclast differentiation</p>	<p>[102]</p> <p>]</p> <p>[103]</p> <p>]</p> <p>[118]</p> <p>]</p> <p>[119]</p> <p>]</p>
	<p>Kupffer cells, HSC</p>	<p>↑ STAT3 signaling → ↑ transforming growth factor (TGF)-β secretion → ↑ HSC activation.</p> <p>↑ STAT3 signaling → ↑ CD14 expression → ↑ responsivity to low-dose bacterial endotoxin.</p> <p>→ ↑ endotoxin-induced hepatic inflammation</p>	<p>↑ hepatic inflammation and NASH</p> <p>↑ hepatic fibrogenesis</p>	<p>[106]</p> <p>]</p> <p>[110]</p> <p>]</p>
	<p>β-cells</p>	<p>↓ intracellular glucose transport via GLUT-2</p>	<p>↓ pancreatic insulin secretion</p>	<p>[102]</p> <p>]</p> <p>[103]</p> <p>]</p>

		Hypothalamic ventromedial nucleus (VHM)	↑ β-adrenergic sympathetic tone→↓ osteoblast proliferation, activity and secretion of uc-osteocalcin (β2 receptor-mediated)	Bone loss	[9]
		Serotonergic brainstem neurons	↑ serotonergic neuron activity→↑ VHM nucleus sympathetic tone		[113]
		Osteoblast	↑ phosphorylation and inactivation of glycogen synthase kinase (GSK)-3β activity→↑ osteoblast differentiation and bone matrix mineralization  ↑ FGF-23 secretion→↓ renal 1,25(OH)2D3 synthesis and phosphate resorption	↑ bone mineralization	[116]
		Renal proximal tubules	↓ 25-OH-D(3)-1α-hydroxylase (CYP27B1) activity→ ↓1,25(OH)2D3 synthesis	↓ bone mineralization	[119]

### TNF-α

Secreting cells	Modulators of secretion	Target cell	Cellular mechanism	Biological effect	Ref.
Adipocytes, macrophages, Kupffer cells, hepatocytes,	<b>Stimulators</b> Oxidative stress <b>Inhibitors</b> adiponectin	Adipocyte	↓ secretion of leptin and adiponectin.  ↓ GLUT-4 expression.  ↓ lipoprotein lipase (LPL) activity.  ↑ hormone-sensitive lipase→↑ lipolysis.	Insulin resistance  Adipose tissue and systemic inflammation	[122] ] [123] ]

			<p>↑ JNK-1 activation → phosphorylation of IRS-1 → insulin receptor signalling inactivation.</p> <p>↑ IKK<math>\beta</math>/NF-<math>\kappa</math>B pathway activation → ↑ apoptosis, proinflammatory cytokine secretion</p>		
		Hepatocyte	<p>↑ JNK-1 activation → phosphorylation of IRS-1 → ↓ insulin receptor signalling.</p> <p>↑ JNK-1 and NF-<math>\kappa</math>B pathway activation → ↑ apoptosis and proinflammatory cytokine secretion</p>	<p>Insulin resistance</p> <p>Hepatic and systemic inflammation</p> <p>NASH</p>	<p>[122 ]</p>
		Kupffer cell	<p>↑ JNK-1 and NF-<math>\kappa</math>B pathway activation → ↑ apoptosis, proinflammatory cytokine secretion</p>	<p>Insulin resistance</p> <p>Hepatic and systemic inflammation</p> <p>NASH</p>	<p>[122 ]</p> <p>[124 ]</p> <p>[125 ]</p>
		Osteoblast	<p>↑ ubiquitination of RUNX2 → ↓ RUNX2 expression → ↓ osteoblast differentiation, proliferation and activation.</p> <p>↓ MAPK pathway activation → ↓ osteoblast differentiation, proliferation and activation.</p> <p>↓ expression of alkaline phosphatase, vitamin D receptor, parathyroid hormone receptor.</p> <p>↑ RANKL secretion</p>	<p>↓ bone formation</p>	<p>[127 ]</p> <p>[130 ]</p>
		Osteoclast	<p>↑ TNF-R1-mediated NF-<math>\kappa</math>B stimulation of osteoclast differentiation.</p>	<p>↑ bone resorption</p>	<p>[126 ]</p> <p>[127 ]</p>

			<p>↑ RANKL-induced stimulation of osteoclast differentiation .</p> <p>↑ rapamycin/S6 kinase activation → ↓ apoptosis</p>		]
<b>Adiponectin</b>					
<b>Secreting cells</b>	<b>Modulators of secretion</b>	<b>Target cell</b>	<b>Cellular mechanism</b>	<b>Biological effect</b>	<b>Ref.</b>
Adipocytes	<p><b>Stimulators</b></p> <p>Weight loss; uc-osteocalcin</p> <p><b>Inhibitors</b></p> <p>TNF-<math>\alpha</math>; IL-6; resistin; insulin; glucocorticoids</p>	Hepatocyte, adipocyte, muscle	<p>↑ AMPK activation → ↑ mitochondrial fatty acid <math>\beta</math>-oxidation.</p> <p>↑ insulin signalling.</p> <p>↓ SREBP-1c expression → ↓ <i>de novo</i> lipogenesis.</p> <p>↓ apoptosis.</p> <p>↓ proinflammatory cytokine secretion.</p>	<p>↓ steatosis</p> <p>↓ hepatic, muscle and adipose tissue insulin resistance</p> <p>↓ hepatic, necroinflammation</p>	<p>[44]</p> <p>[131]</p> <p>[132]</p> <p>[132]</p>
		Hepatic stellate cell	<p>↑ apoptosis.</p> <p>↓ activity and collagen deposition.</p>	↓ fibrogenesis	<p>[131]</p> <p>[132]</p>
		Osteoblast	<p>↑ proliferation, differentiation and activity.</p> <p>↑ RANKL secretion.</p> <p>↓ osteoprotegerin secretion.</p>	<p>↑ bone deposition</p>	<p>[61]</p> <p>[62]</p> <p>[134]</p>
		Osteoclast	<p>↓ APPL1-mediated Akt1 activity → ↓ RANKL-induced osteoclastogenesis</p> <p>↑ osteoclast apoptosis.</p> <p>↓ survival/proliferation of osteoclast precursor cells.</p>	↓ bone resorption	[135]

**Abbreviations:** SMC: smooth muscle cells; HCC: hepatocellular carcinoma; PI3-K : phosphoinositide 3-kinase; Akt: protein kinase B; APPL1: adaptor protein containing pleckstrin homology domain, phosphotyrosine domain, and leucine zipper motif) HIF-1: hypoxia-inducible factor-1; NF- $\kappa$ B: nuclear factor- $\kappa$ B; MMP: matrix metalloproteinase; ECM: extracellular matrix; uPA: urokinase-type plasminogen activator; VEGF: vascular endothelial growth factor ; JNK: c-Jun NH2-terminal kinase; BMD: bone mineral density; PTH: parathyroid hormone; ERK: extracellular signal-regulated protein kinase; TNF: tumor necrosis factor; MCP: monocyte chemoattractant protein; PPAR: peroxisome proliferator-activated; STAT3: signal transducer and activator of transcription 3; GSK-3 $\beta$ : glycogen synthase kinase-3; PEPCK: phosphoenolpyruvate carboxykinase; G6P: glucose 6 phosphatase; SREBF: sterol regulatory binding protein; DGAT: diacylglycerol acyltransferase; FoxO1: Forkhead box 01; NKT: naturalkiller T ; TGF: transforming growth factor; PI3-K: phosphoinositide 3-kinase; pAkt, phosphorylated Akt; NR4A2: nuclear receptor subfamily 4, group A, member 2; miRNA: microRNA; EGF: epidermal growth factor; eIF2 $\alpha$ :  $\alpha$ -subunit of eukaryotic initiation factor 2; IRE-1 $\alpha$ : inositol-requiring enzyme-1 $\alpha$ ; PERK: protein kinase–like endoplasmic reticulum kinase; UCP: uncoupling protein; PGC-1 $\alpha$ : peroxisome proliferator-activated receptor  $\gamma$  (PPAR- $\gamma$ ) coactivator-1 $\alpha$ ; RANK: receptor activator of nuclear factor- $\kappa$ B; RANKL: receptor activator of nuclear factor- $\kappa$ B ligand; TZD: thiazolidinediones; IL-1 $\beta$ : interleukin 1- $\beta$ ; TRAF6: TNF receptor-associated factor 6; TRAIL: TNF-related apoptosis-inducing ligand; IRS-1: insulin receptor substrate-1; TLR: toll-like receptor; CPT : carnitine palmitoyltransferase; JAK: janus kinase; GLUT-2: glucose transporter 2; POMC: proopiomelanocortin; TGF: transforming growth factor; AMPK: 5'adenosine monophosphate -activated protein kinase; FGF-23: fibroblast growth factor 23;



## REFERENCES

---

- 1 Kim HY, et al. (2010). Negative association between metabolic syndrome and bone mineral density in Koreans, especially in men. *Calcif Tissue Int* 86, 350–8
- 2 Jeon YK, et al. (2011). Association between bone mineral density and metabolic syndrome in preand postmenopausal women. *Endocr J* 58: 87–93.
- 3 Li M, et al. (2012). Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Osteoporotic Fracture in Middle-Aged and Elderly Chinese. *J Clin Endocrinol Metab* 97: 2033–8.
- 4 Pirgon O, et al. (2011). Correlation of insulin sensitivity with bone mineral status in obese adolescents with nonalcoholic fatty liver disease. *Clin Endocrinol (Oxf)* 75: 189–95.
- 5 Pardee PE, et al.(2012). Non-alcoholic fatty liver disease is associated with low bone mineral density in obese children. *Aliment Pharmacol Ther* 35: 248–54
- 6 Moon SS, et al.(2012). Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. *Endocrine* 2012; doi:10.1007/ s12020-012-9639-6.
- 7 Campos RM, et al. (2012). The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. *Endocrine* 2012; doi:10.1007/s12020- 012-9613-3.
- 8 de Paula FJA, et al. (2010). Novel Insights into the Relationship between Diabetes and Osteoporosis. *Diabetes Metab Res Rev.* 26: 622–30
- 9 Confavreux CB. (2011) Bone: from a reservoir of minerals to a regulator of energy metabolism. *Kidney International* 79 (Suppl 121), S14–19.
- 10 Cao DX et al. (2012). Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. *World J Gastroenterol* 18: 3923-30
- 11 Gimba ER and Tilli TM. (2013). Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways. *Cancer Lett.* 331:11-7.
- 12 Bertola A, et al. (2009). Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. *Diabetes.* 58:125-33.

- 
- <sup>13</sup> Yilmaz Y, et al. (2013). Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease. *Dig Liver Dis.* 45:58-62
- <sup>14</sup> Lima-Cabello E, et al. (2011). Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. *Clin Sci (Lond)* 120: 239–50
- <sup>15</sup> Syn, W.K. et al (2012) NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease *Gut.* 61: 1323-29
- <sup>16</sup> Chapman J, et al. (2010) Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. *PLoS One.* 5: e13959
- <sup>17</sup> Zeyda M, et al. (2011). Osteopontin is an activator of human adipose tissue macrophages and directly affects adipocyte function. *Endocrinology.* 152: 2219-27.
- <sup>18</sup> Kiefer FW, et al.(2011). Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. *Diabetologia.*54: 2132-42
- <sup>19</sup> Kiefer FW, et al. (2010) Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. *Diabetes.* 59: 935-46.
- <sup>20</sup> Syn WK, et al. (2011). Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. *Hepatology* 53: 106-15
- <sup>21</sup> Chang IC, et al.(2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. *Osteoporos Int.* 21:1401-9
- <sup>22</sup> Chiang, T.I. et al (2011) Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. *Osteoporos Int.* 22, 577–585.

- 
- <sup>23</sup> Kennedy, O.D. et al. (2009) Effects of ovariectomy on bone turnover, porosity, and biomechanical properties in ovine compact bone 12 months postsurgery. *J Orthop Res.* 27,303–309
- <sup>24</sup> Musso G, et al. (2012) Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. *Hepatology* 56:933-42.
- <sup>25</sup> Urtasun R, et al.(2012). Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin  $\alpha(V)\beta(3)$  engagement and PI3K/pAkt/NF $\kappa$ B signaling. *Hepatology* 55:594-608
- <sup>26</sup> Zhao J, et al. (2008). Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. *Gastroenterology* 2008; 135: 956-968
- <sup>27</sup> Sun BS, et al. (2008). Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. *Hepatology* 48: 1834-1842
- <sup>28</sup> Weber GF, et al. (2010). Osteopontin is a marker for cancer aggressiveness and patient survival. *Br J Cancer* 103: 861-869
- <sup>29</sup> Dong QZ, et al.(2013). Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma. *Hepatology.* 57:1024-34
- <sup>30</sup> Chen RX, et al.(2011). Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via mechanism involving MMP-2 and uPA. *Oncol Rep* 25: 803-808
- <sup>31</sup>Chae S, et al. (2009) Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. *Int. J. Oncol.* 35: 1409–16.
- <sup>32</sup> Bhattacharya SD, et al.(2010). Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines. *Surgery* 148: 291-97
- <sup>33</sup> Movahed A, et al.(2012). Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. *J Bone Miner Metab.* 30: 683-91.

- 
- <sup>34</sup> Ngarmukos C. et al. (2012) A reduced serum level of total osteocalcin in men predicts the development of diabetes in a long-term follow-up cohort. *Clinical Endocrinology* 77 : 42–46
- <sup>35</sup> Oosterwerff MM, et al. (2013). Osteocalcin as a predictor of the metabolic syndrome in older persons: a population-based study. *Clin Endocrinol (Oxf)*. 78:242-7.
- <sup>36</sup> Bezerra dos Santos Magalhães K, et al.(2013). Metabolic Syndrome and Central Fat Distribution Are Related to Lower Serum Osteocalcin Concentrations. *Ann Nutr Metab* 62:181–186
- <sup>37</sup> Iki M, et al(2012). Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. *Osteoporos Int*. 23: 761-70
- <sup>38</sup> Bao Y, et al.(2013). Inverse relationship between serum osteocalcin levels and visceral fat area in Chinese men. *J Clin Endocrinol Metab*. 98:345-51
- <sup>39</sup> Greco EA, et al. (2013). Negative association between trunk fat, insulin resistance and skeleton in obese women. *World J Diabetes* 4: 31-39
- <sup>40</sup> Fernández-Real JM, et al.(2010). Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. *Osteoporos Int*. 21:2101-7.
- <sup>41</sup> Dou J, et al. (2013). Relationship between serum osteocalcin levels and non-alcoholic fatty liver disease in Chinese men. *Clin Exp Pharmacol Physiol*. 40: 282-8.
- <sup>42</sup> Yilmaz Y, et al(2011). Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: association with ballooning degeneration. *Scand J Clin Lab Invest*. 71:631-6.
- <sup>43</sup> Aller R, et al.(2011) Relation of osteocalcin with insulin resistance and histopathological changes of non alcoholic fatty liver disease. *Ann Hepatol*. 10:50-5.

- 
- <sup>44</sup> Ferron M, et al. (2008). Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. *Proc Natl Acad Sci U S A* 105: 5266–70
- <sup>45</sup> Ferron M, et al. (2012). Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice. *Bone* 50: 568–575
- <sup>46</sup> Fulzele K, , et al. (2010). Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. *Cell*. 142: 309–19
- <sup>47</sup> Rached MT, et al. (2010) FoxO1 expression in osteoblasts regulates glucose homeostasis through regulation of osteocalcin in mice. *J Clin Invest*. 120:357-68
- <sup>48</sup> Yang S, et al.(2011) Foxo1 mediates insulin-like growth factor 1 (IGF1)/insulin regulation of osteocalcin expression by antagonizing Runx2 in osteoblasts. *J Biol Chem*. 286:19149-58.
- <sup>49</sup> Ferron M, et al. (2010). Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy Metabolism. *Cell*. 142:296–308.
- <sup>50</sup> Kode A, et al. (2012). FoxO1 protein cooperates with ATF4 protein in osteoblasts to control glucose homeostasis.. *J Biol Chem*. 287: 8757-68
- <sup>51</sup> Zhou B, et al. (2013).Osteocalcin Reverses Endoplasmic Reticulum Stress and Improves Impaired Insulin Sensitivity Secondary to Diet-Induced Obesity Through Nuclear Factor- $\kappa$ B Signaling Pathway. *Endocrinology* 154: 1055–106
- <sup>52</sup> Ducy P, et al. (1996). Increased bone formation in osteocalcin-deficient mice. *Nature* 382:448–

- 
- <sup>53</sup> Bullò M, et al.(2012). Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and b cell function in elderly men at high cardiovascular risk. *Am J Clin Nutr* 95:249–55
- <sup>54</sup> Pi M & Quarles LD. (2012). Multiligand specificity and wide tissue expression of GPRC6A reveals new endocrine networks. *Endocrinology* 153: 2062-9
- <sup>55</sup> Pi M, et al.(2011). GPRC6A mediates responses to osteocalcin in  $\beta$ -cells in vitro and pancreas in vivo. *J Bone Miner Res.* : 1680-3
- <sup>56</sup> Mizokami A, et al.(2013) Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. *PLoS One.* ;8:e57375
- <sup>57</sup> Mori K, et al.(2012). Undercarboxylated osteocalcin does not correlate with insulin resistance as assessed by euglycemic hyperinsulinemic clamp technique in patients with type 2 diabetes mellitus. *Diabetol Metab Syndr.* 2012; 4: 53
- <sup>58</sup> Abseyi N, et al. (2012). Relationships between osteocalcin, glucose metabolism, and adiponectin in obese children: is there crosstalk between bone tissue and glucose metabolism? *J Clin Res Pediatr Endocrinol.* 4:182-8.
- <sup>59</sup> Reid, P and Holen, I. (2009) Pathophysiological roles of osteoprotegerin (OPG). *Eur J Cell Biol.* 88, 1–17.
- <sup>60</sup> Schneeweis, L.A., et al. (2005). Functional dissection of osteoprotegerin and its interaction with receptor activator of NF- $\kappa$ B ligand. *J. Biol. Chem.* 280, 41155–64.
- <sup>61</sup> Luo XH, et al.(2006). Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. *J Bone Miner Res.* 21: 1648-56.

- 
- <sup>62</sup> Wang QP, et al. (2012). Effects of 17 $\beta$ -estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor- $\kappa$ B ligand. *Bone* 51: 515–23.
- <sup>63</sup> Vijayan V, et al.(2013).Homocysteine alters the osteoprotegerin/RANKL system in the osteoblast to promote bone loss: pivotal role of the redox regulator forkhead O1. *Free Radic Biol Med.* 61C:72-84.
- <sup>64</sup> Harsløf T, et al. (2011).The expression and regulation of bone-acting cytokines in human peripheral adipose tissue in organ culture. *Horm Metab Res.* 2011;43:477-82.
- <sup>65</sup> Scholtyssek C, et al. (2013). PPAR $\beta/\delta$  governs Wnt signaling and bone turnover. *Nat Med.* 2013 Mar 31. doi: 10.1038/nm.3146. [Epub ahead of print]
- <sup>66</sup>Kleyer A, et al.(2012). Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. *J Bone Miner Res.* 27:2442-51
- <sup>67</sup> Musso G, et al.(2012). Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia.* 55: 885-904
- <sup>68</sup> Musso G, et al.(2013). Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. *Prog Lipid Res.* 52:175-91
- <sup>69</sup> Beck GR Jr, et al. (2013). The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. *Transl Res.* 161: 145-55.

- 
- <sup>70</sup> Stern, A. et al. (2007) The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB ligand with bone mineral density in older adults: the Rancho Bernardo study. *Eur J Endocrinol* . 156, 555–562.
- <sup>71</sup> Mezquita-Raya, P. et al. (2005) The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. *Osteoporos Int*. 16, 1368–1374.
- <sup>72</sup> Ashley DT, et al. (2011). Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects. *Metabolism*. 60: 994-1000.
- <sup>73</sup> Pepene CE, et al. (2011) Circulating osteoprotegerin and soluble receptor activator of nuclear factor  $\kappa$ B ligand in polycystic ovary syndrome: relationships to insulin resistance and endothelial dysfunction. *Eur J Endocrinol*. 164: 61-8.
- <sup>74</sup> Nabipour I, et al. (2010). Osteoprotegerin in relation to type 2 diabetes mellitus and the metabolic syndrome in postmenopausal women. *Metabolism*. 59: 742-7
- <sup>75</sup> Yilmaz, Y. et al. (2010) Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. *Scand J Clin Lab Invest*. 70, 541–546.
- <sup>76</sup> McClung MR, et al. (2006). Denosumab in postmenopausal women with low bone mineral density. *N Engl J Med* 354:821–831
- <sup>77</sup> Kiechl S, et al.(2013). Blockade of receptor activator of nuclear factor- $\kappa$ B (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. *Nat Med*. 19:358-63
- <sup>78</sup> Mori K et al, (2011) Fetuin-A: a multifunctional protein. *Recent Pat Endocr Metab Immune Drug Discov.*;5:124-46.
- <sup>79</sup> Mathews ST et al (2006) Fetuin-null mice are protected against obesity and insulin resistance associated with aging. *Biochem Biophys Res Commun.*;350:437-43.
- <sup>80</sup> Hennige AM, et al. (2008). Fetuin-A induces cytokine expression and suppresses adiponectin production. *PLoS ONE* 3: e1765



- 
- <sup>81</sup> Siddiq A et al. (2005). A synonymous coding polymorphism in the  $\alpha$ 2-Heremans-Schmid glycoprotein gene is associated with type-2 diabetes in French Caucasians. *Diabetes* 54: 2477–81.
- <sup>82</sup> Ou HY, et al. (2011). Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. *Clin Endocrinol (Oxf)*. ;75:450-5.
- <sup>83</sup> Xu Y (2011) Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. *Atherosclerosis*. 216:180-6.
- <sup>84</sup> Sun Q, et al. (2013). Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. *Diabetes*. 62:49-55.
- <sup>85</sup> Mori K, (2008) Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. *Metabolism* 57:1248-52.
- <sup>86</sup> Stefan N et al, (2006) Alpha2-Heremans–Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. *Diabetes Care* 29 853–857
- <sup>87</sup> Yilmaz Y et al (2010) Serum fetuin A/ $\alpha$ 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. *Annals of Clinical Biochemistry*
- <sup>88</sup> Kahraman A, et al.(2013) Fetuin-A mRNA expression is elevated in NASH compared to NAFL patients.. *Clin Sci (Lond)*. 2013 Apr 30. [Epub ahead of print]PMID: 23627434
- <sup>89</sup> Haukeland JW (2012 ) Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. *Eur J Endocrinol*.;166: 503-10.
- <sup>90</sup> Ou HY, et al. (2012).Endoplasmic Reticulum Stress Induces the Expression of Fetuin-A to Develop Insulin Resistance. *Endocrinology* 153: 2974–84
- <sup>91</sup> Pal D, et al. (2012). Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. *Nat Med*. 2012 Jul 29. doi: 10.1038/nm.2851. [Epub ahead of print]

- 
- <sup>92</sup> Jahnke-Dechent W, (201) Fetuin-A regulation of calcified matrix metabolism. *Circ Res.* 108:1494-509.
- <sup>93</sup> Herrmann M, et al. (2012). Fetuin-A Function in Systemic Mineral Metabolism. *Trends Cardiovasc Med.* 22:197-201
- <sup>94</sup> Herrmann M, et al. (2012). Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor- A. *Circ Res* 111:1–26
- <sup>95</sup> Price et al (2009) Mineralization by inhibitor exclusion: the calcification of collagen with fetuin. *The Journal of Biological Chemistry*, 284, 17092–101.
- <sup>96</sup> Toroian, D. & Price, P.A. (2008) The essential role of fetuin in the serum-induced calcification of collagen. *Calcified Tissue International*, 82, 116–26.
- <sup>97</sup> Binkert C. Et al (1999) Regulation of osteogenesis by fetuin. *The Journal of Biological Chemistry*, 274: 28514–20.
- <sup>98</sup> Seto J, et al.(2012) Accelerated growth plate mineralization and foreshortened proximal limb bones in fetuin-A knockout mice. *PLoS One.* 7: e47338.
- <sup>99</sup> Ix, J.H et al (2009) Fetuin-A and BMD in older persons: the Health Aging and Body Composition (Health ABC) study. *Journal of Bone and Mineral Research*, 24, 514–521.
- <sup>100</sup> Rasul S (2012) Levels of fetuin-A relate to the levels of bone turnover biomarkers in male and female patients with type 2 diabetes. *Clin Endocrinol (Oxf).*;76: 499-505.
- <sup>101</sup> Amitani M, et al. (2013). The role of leptin in the control of insulin-glucose axis. *Front Neurosci.* 2013 Apr 8;7:51. doi: 10.3389/fnins.2013.00051.

- 
- <sup>102</sup> Miyamoto L. et al. (2012) Leptin activates hepatic 5'AMP-Activated Protein Kinase through sympathetic nervous system and  $\alpha 1$  adrenergic receptor: A potential mechanism for improvement of fatty liver in lipodystrophy by leptin. *J Biol Chem.* 287: 40441-7.
- <sup>103</sup> Huynh FK, et al. (2013). A role for hepatic leptin signaling in lipid metabolism via altered very low density lipoprotein composition and liver lipase activity in mice. *Hepatology.* 201357: 543-54..
- <sup>104</sup> Minokoshi Y, et al.(2002). Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. *Nature* 415: 339-343
- <sup>105</sup> Ebihara K, et al.(2007). Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. *J Clin Endocrinol Metab* 92: 532-541
- <sup>106</sup> Lee JH, et al.(2006) Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipodystrophy and metabolic syndrome induced by the highly active antiretroviral therapy. *J Clin Endocrinol Metab* 91: 2605-2611
- <sup>107</sup> Machado MV, etl al. (2012) How adiponectin, leptin, and ghrelin orchestrate together and Correlate with the severity of nonalcoholic fatty liver disease. *Eur J Gastroenterol Hepatol* 24:1166–1172
- <sup>108</sup> Kalra,S.P. et al. (2011).Pivotal role of leptin-hypothalamus signalling in the etiology of diabetes uncovered by gene therapy: a new therapeutic intervention? *Gene Ther.* 18, 319–325.
- <sup>109</sup> St-Pierre,J.,and Tremblay,M.L. (2012). Modulation of leptin resistance by protein tyrosine phosphatases. *Cell Metab.* 15, 292–297.
- <sup>110</sup> Imajo K, et al.(2012). Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. *Cell Metab.* 16:44-54

- 
- <sup>111</sup> Zhang W, et al. (2013). Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells. *Int J Biochem Cell Biol.* 45:736-44
- <sup>112</sup> Tilg H and Moschen AR. (2010). Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 52:1836-46
- <sup>113</sup> Yadav, V.K. et al. (2009) A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. *Cell* 138, 976–989.
- <sup>114</sup> Ducy, P. et al.(200) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. *Cell* 100, 197–207
- <sup>115</sup> Takeda, S. et al. (2002) Leptin regulates bone formation via the sympathetic nervous system. *Cell.* 111, 305–317.
- <sup>116</sup> Zeadin MG, et al.(2012).Leptin promotes osteoblast differentiation and mineralization of primary cultures of vascular smooth muscle cells by inhibiting glycogen synthase kinase (GSK)-3 $\beta$ . *Biochem Biophys Res Commun.* 425: 924-30
- <sup>117</sup> Hedbacker K, et al.(2010). Antidiabetic effects of IGFBP2, a leptin-regulated gene. *Cell Metab*11:11–22.
- <sup>118</sup> DeMambro VE, et al.(2012) Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. *J Bone Miner Res.* 27:390-400.
- <sup>119</sup> Tsuji, K. Et al. (2010) Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1 $\alpha$ ,25-dihydroxyvitamin D3 synthesis in leptin-deficient ob/ob mice. *J Bone Miner Res* 25, 1711–1723.
- <sup>120</sup> Morcov C, et al. (2012) Correlation between adiponectin, leptin, insulin growth factor-1 and bone mineral density in pre and postmenopausal women. *Rev Med Chir Soc Med Nat Iasi.* 116: 785-9.

- 
- <sup>121</sup> Campos RM, et al. (2013) Interaction of bone mineral density, adipokines and hormones in obese adolescents girls submitted in an interdisciplinary therapy. *J Pediatr Endocrinol Metab.* 2013 Apr 22:1-6. doi: 10.1515/jpem-2012-0336. [Epub ahead of print]
- <sup>122</sup> Gambino R et al. (2011) Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. *Antioxid Redox Signal.* 15: 1325-65.
- <sup>123</sup> Federico A et al. (2010) Fat: a matter of disturbance for the immune system. *World J Gastroenterol* 16: 4762–72.
- <sup>124</sup> Koca SS. Et al (2008) The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. *Inflammation.*31: 91-8.
- <sup>125</sup> Alaaeddine N, et al. (2012) TNF- $\alpha$  messenger ribonucleic acid (mRNA) in patients with nonalcoholic steatohepatitis. *Eur Cytokine Netw.* 23:107-11.
- <sup>126</sup> Zou W et al (2001) Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. *Cell Biochem.* 83: 70-83.
- <sup>127</sup> Kawai VK (2012) Effects of anti-tumor necrosis factor  $\alpha$  agents on bone. *Curr Opin Rheumatol.* 24:576-85.
- <sup>128</sup> Lee HL et al (2010). Msx2 mediates the inhibitory action of TNF-alpha on osteoblast differentiation. *Exp Mol Med* ; 42:437–445.
- <sup>129</sup> Ochi H et al (2010). The roles of TNFR1 in lipopolysaccharide-induced bone loss: dual effects of TNFR1 on bone metabolism via osteoclastogenesis and osteoblast survival. *J Orthop Res*; 28:657–663.
- <sup>130</sup> Nanes MS (2003). Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology.. *Gene.* 321:1-15.

- 
- <sup>131</sup> Calton EK, et al.(2013) . Factors determining the risk of the metabolic syndrome: is there a central role for adiponectin? *Eur J Clin Nutr.* 67: 485-91.
- <sup>132</sup>Musso G, et al. (2010).Emerging molecular targets for the treatment of non-alcoholic fatty liver disease. *Annu Rev Med.* 61: 375-92.
- <sup>133</sup> Xu A, et al. (2003). The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. *J Clin Invest* 112: 91-100
- <sup>134</sup> Williams GA, et al. (2009). *In Vitro* and *in Vivo* Effects of Adiponectin on Bone. *Endocrinology* 150: 3603–3610
- <sup>135</sup> Tu Q, et al.(2011). Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. *J Biol Chem.* 286:12542-53
- <sup>136</sup> Biver E, et al.(2011). Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 96:2703-13.
- <sup>137</sup> Pluskiewicz W, ET AL.(2012) . Adiponectin and resistin in relationship with skeletal status in women from the RAC-OST-POL study. *Endokrynol Pol.* 63: 427-31.
- <sup>138</sup> Johansson H, et al. (2012).High serum adiponectin predicts incident fractures in elderly men: Osteoporotic fractures in men (MrOS) Sweden. *J Bone Miner Res.* 27:1390-6.
- <sup>139</sup>Kanazawa I, et al.(2010). Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1-year treatment of type 2 diabetes mellitus. *Metabolism.* 59:1252-6

---

<sup>140</sup>Tenta R, et al.(2012). Association between circulating levels of adiponectin and indices of bone mass and bone metabolism in middle-aged post-menopausal women. *J Endocrinol Invest.* 35:306-11.

<sup>141</sup>Schafer AL, et al. (2011). Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). *Clin Endocrinol Metab.* 96:E1982-9